| Year |
Citation |
Score |
| 2024 |
Larivière Y, Matuvanga TZ, Osang'ir BI, Milolo S, Meta R, Kimbulu P, Robinson C, Katwere M, McLean C, Lemey G, Matangila J, Maketa V, Mitashi P, Van Geertruyden JP, Van Damme P, et al. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial. The Lancet. Infectious Diseases. PMID 38552653 DOI: 10.1016/S1473-3099(24)00058-6 |
0.433 |
|
| 2023 |
Poulimeneas D, Koniordou M, Kousi D, Merakou C, Kopsidas I, Tsopela GC, Argyropoulos CD, Themistocleous SC, Shiamakkides G, Constantinou M, Alexandrou A, Noula E, Nearchou A, Salmanton-García J, Stewart FA, ... ... van Damme P, et al. The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities: An Internal Expert Consultation of the VACCELERATE Consortium. Vaccines. 11. PMID 38140188 DOI: 10.3390/vaccines11121784 |
0.51 |
|
| 2023 |
Marchant A, Van Damme P, Plotkin S, Neels P, Cassetti MC, Cramer J, Gruber MF, Goldblatt D, King D, Hartig-Merkel W, Vandeputte J. Enabling the evaluation of COVID-19 vaccines with correlates of protection. Biologicals : Journal of the International Association of Biological Standardization. 85: 101723. PMID 37976940 DOI: 10.1016/j.biologicals.2023.101723 |
0.607 |
|
| 2023 |
Van Damme P, Pintó RM, Feng Z, Cui F, Gentile A, Shouval D. Hepatitis A virus infection. Nature Reviews. Disease Primers. 9: 51. PMID 37770459 DOI: 10.1038/s41572-023-00461-2 |
0.362 |
|
| 2023 |
Larivière Y, Garcia-Fogeda I, Zola Matuvanga T, Isekah Osang'ir B, Milolo S, Meta R, Kimbulu P, Robinson C, Katwere M, McLean C, Hens N, Matangila J, Maketa V, Mitashi P, Muhindo-Mavoko H, ... ... Van Damme P, et al. Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo. The Journal of Infectious Diseases. PMID 37673423 DOI: 10.1093/infdis/jiad350 |
0.458 |
|
| 2023 |
Salmanton-García J, Wipfler P, Valle-Simón P, Merakou C, Kopsidas I, Bethe U, Steinbach A, Spivak O, Součková L, Mendonça MA, Koniordou M, Hellemans M, Frías-Iniesta J, Davis RJ, Barta I, ... ... van Damme P, et al. VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe. Vaccine. PMID 37210309 DOI: 10.1016/j.vaccine.2023.05.006 |
0.494 |
|
| 2023 |
Ekinci E, Willen L, Rodriguez Ruiz JP, Maertens K, Van Heirstraeten L, Serrano G, Wautier M, Deplano A, Goossens H, Van Damme P, Beutels P, Malhotra-Kumar S, Martiny D, Theeten H. carriage and antibiotic resistance profile in Belgian infants over a three-year period (2016-2018). Frontiers in Microbiology. 14: 1160073. PMID 37168112 DOI: 10.3389/fmicb.2023.1160073 |
0.329 |
|
| 2023 |
Waheed DE, Bolio A, Guillaume D, Sidibe A, Morgan C, Karafillakis E, Holloway M, Van Damme P, Limaye R, Vorsters A. Planning, implementation, and sustaining high coverage of human papillomavirus (HPV) vaccination programs: What works in the context of low-resource countries? Frontiers in Public Health. 11: 1112981. PMID 37124764 DOI: 10.3389/fpubh.2023.1112981 |
0.395 |
|
| 2023 |
Trzebinski W, Claessens T, Buhmann J, De Waele A, Hendrickx G, Van Damme P, Daelemans W, Poels K. The effects of expressing empathy/autonomy-support by a COVID-19 vaccination chatbot: an experimental study in a sample of Belgian adults. Jmir Formative Research. PMID 37074978 DOI: 10.2196/41148 |
0.535 |
|
| 2023 |
Bonanni P, Steffen R, Schelling J, Balaisyte-Jazone L, Posiuniene I, Zatoński M, Van Damme P. Vaccine co-administration in adults: An effective way to improve vaccination coverage. Human Vaccines & Immunotherapeutics. 19: 2195786. PMID 37039318 DOI: 10.1080/21645515.2023.2195786 |
0.608 |
|
| 2023 |
Beyens M, Toscano A, Van Damme P, Dogné JM, Ebo DG, Sabato V. Perceived high risk of COVID-19 vaccination: The revealing power of placebo. The Journal of Allergy and Clinical Immunology. in Practice. PMID 36965707 DOI: 10.1016/j.jaip.2023.03.031 |
0.459 |
|
| 2023 |
Tschismarov R, Van Damme P, Germain C, De Coster I, Mateo M, Reynard S, Journeaux A, Tomberger Y, Withanage K, Haslwanter D, Terler K, Schrauf S, Müllner M, Tauber E, Ramsauer K, et al. Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial. Lancet (London, England). PMID 36934733 DOI: 10.1016/S0140-6736(23)00048-X |
0.512 |
|
| 2023 |
Argyropoulos CD, Leckler J, Salmanton-García J, Constantinou M, Alexandrou A, Themistocleous S, Noula E, Shiamakkides G, Nearchou A, Stewart FA, Albus K, Koniordou M, Kopsidas I, Spivak O, Hellemans M, ... ... van Damme P, et al. Enhancing public health communication of vaccine trials: The pan-European VACCELERATE Toolkit. Jmir Public Health and Surveillance. PMID 36878478 DOI: 10.2196/44491 |
0.519 |
|
| 2023 |
Andani A, Bunge E, Kassianos G, Eeuwijk J, Mellou K, Van Damme P, Mukherjee P, Steffen R. Hepatitis A Occurrence and Outbreaks in Europe Over the Past Two Decades: a Systematic Review. Journal of Viral Hepatitis. PMID 36825922 DOI: 10.1111/jvh.13821 |
0.452 |
|
| 2023 |
De Brabandere L, Hendrickx G, Poels K, Daelemans W, Van Damme P, Maertens K. Influence of the COVID-19 pandemic and social media on the behaviour of pregnant and lactating women towards vaccination: a scoping review. Bmj Open. 13: e066367. PMID 36764726 DOI: 10.1136/bmjopen-2022-066367 |
0.484 |
|
| 2023 |
Erdem R, De Coster I, Withanage K, Mercer LD, Marchant A, Taton M, Cools N, Lion E, Cassels F, Higgins D, Ivinson K, Locke E, Mahmood K, Wright PF, Gast C, ... ... Van Damme P, et al. Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study. Vaccine. PMID 36746739 DOI: 10.1016/j.vaccine.2023.01.048 |
0.423 |
|
| 2022 |
Ekinci E, Van Heirstraeten L, Willen L, Desmet S, Wouters I, Vermeulen H, Lammens C, Goossens H, Van Damme P, Verhaegen J, Beutels P, Theeten H, Malhotra-Kumar S. Serotype 19A and 6C account for one third of pneumococcal carriage among Belgian day-care children four years after a shift to a lower-valent PCV. Journal of the Pediatric Infectious Diseases Society. PMID 36377804 DOI: 10.1093/jpids/piac117 |
0.436 |
|
| 2022 |
Bechini A, Chiesi F, Giammarco B, Gori E, Di Tommaso M, Strambi N, Alti E, Picciolli P, Mereu G, Mori MG, Vitali Rosati G, Van Damme P, Bamberger M, Bonanni P, Boccalini S. Electronic Package Leaflets for Vaccines: What Are People's Perceptions in Italy? Vaccines. 10. PMID 35891238 DOI: 10.3390/vaccines10071075 |
0.462 |
|
| 2022 |
Zola Matuvanga T, Larivière Y, Lemey G, De Bie J, Milolo S, Meta R, Esanga E, Vermeiren PP, Thys S, Van Geertruyden JP, Van Damme P, Maketa V, Matangila J, Mitashi P, Muhindo-Mavoko H. Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned. Vaccine. 40: 3470-3480. PMID 35550847 DOI: 10.1016/j.vaccine.2022.04.094 |
0.488 |
|
| 2022 |
Verleye A, Wijtvliet V, Abrams S, Hellemans R, Bougrea R, Massart A, Pipeleers L, Wissing KM, Ariën KK, De Winter BY, Van Damme P, Abramowicz D, Ledeganck KJ. Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. PMID 35544087 DOI: 10.1093/ndt/gfac174 |
0.543 |
|
| 2022 |
Folschweiller N, Vanden Abeele C, Chu L, Van Damme P, García-Sastre A, Krammer F, Nachbagauer R, Palese P, Solórzano A, Bi D, David MP, Friel D, Innis BL, Koch J, Mallett CP, et al. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial. The Lancet. Infectious Diseases. PMID 35461522 DOI: 10.1016/S1473-3099(22)00024-X |
0.527 |
|
| 2022 |
Vojtek I, Larson H, Plotkin S, Van Damme P. Evolving measles status and immunization policy development in six European countries. Human Vaccines & Immunotherapeutics. 1-15. PMID 35180372 DOI: 10.1080/21645515.2022.2031776 |
0.534 |
|
| 2022 |
Karafillakis E, Van Damme P, Hendrickx G, Larson HJ. COVID-19 in Europe: new challenges for addressing vaccine hesitancy. Lancet (London, England). 399: 699-701. PMID 35123665 DOI: 10.1016/S0140-6736(22)00150-7 |
0.575 |
|
| 2022 |
Elias G, Meysman P, Bartholomeus E, De Neuter N, Keersmaekers N, Suls A, Jansens H, Souquette A, De Reu H, Emonds MP, Smits E, Lion E, Thomas PG, Mortier G, Van Damme P, et al. Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon hepatitis B vaccination. Elife. 11. PMID 35074048 DOI: 10.7554/eLife.68388 |
0.399 |
|
| 2022 |
Bamberger M, De Loof H, Marstboom C, Oury S, Bonanni P, Launay O, Kojouharova M, Van Damme P. Replacing vaccine paper package inserts: a multi-country questionnaire study on the acceptability of an electronic replacement in different target groups. Bmc Public Health. 22: 156. PMID 35073891 DOI: 10.1186/s12889-022-12510-8 |
0.454 |
|
| 2022 |
Wijtvliet VPWM, Ariën KK, Abrams S, Couttenye MM, Mestrez F, Mariën J, De Winter BY, Van Damme P, Pipeleers L, Wissing KM, Abramowicz D, Ledeganck KJ. mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients? Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 37: 799-803. PMID 34888697 DOI: 10.1093/ndt/gfab352 |
0.361 |
|
| 2021 |
Valckx S, Crèvecoeur J, Verelst F, Vranckx M, Hendrickx G, Hens N, Van Damme P, Pepermans K, Beutels P, Neyens T. Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July-December 2020). Vaccine. 40: 151-161. PMID 34863621 DOI: 10.1016/j.vaccine.2021.10.073 |
0.608 |
|
| 2021 |
Orije MRP, García-Fogeda I, Van Dyck W, Corbière V, Mascart F, Mahieu L, Hens N, Van Damme P, Cools N, Ogunjimi B, Maertens K, Leuridan E. Impact of maternal pertussis antibodies on the infants' cellular immune responses. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 34849638 DOI: 10.1093/cid/ciab972 |
0.383 |
|
| 2021 |
Withanage K, De Coster I, Cools N, Viviani S, Tourneur J, Chevandier M, Lambiel M, Willems P, Le Vert A, Nicolas F, Van Damme P. Phase 1 randomized, placebo-controlled, dose-escalating study to evaluate OVX836, a nucleoprotein-based influenza vaccine: intramuscular results. The Journal of Infectious Diseases. PMID 34653245 DOI: 10.1093/infdis/jiab532 |
0.496 |
|
| 2021 |
Vesikari T, Finn A, van Damme P, Leroux-Roels I, Leroux-Roels G, Segall N, Toma A, Vallieres G, Aronson R, Reich D, Arora S, Ruane PJ, Cone CL, Manns M, Cosgrove C, et al. Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial. Jama Network Open. 4: e2128652. PMID 34636914 DOI: 10.1001/jamanetworkopen.2021.28652 |
0.607 |
|
| 2021 |
Pattyn J, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B Vaccines. The Journal of Infectious Diseases. 224: S343-S351. PMID 34590138 DOI: 10.1093/infdis/jiaa668 |
0.565 |
|
| 2021 |
Larivière Y, Zola T, Stoppie E, Maketa V, Matangila J, Mitashi P, De Bie J, Muhindo-Mavoko H, Van Geertruyden JP, Van Damme P. Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol. Bmj Open. 11: e046835. PMID 34588237 DOI: 10.1136/bmjopen-2020-046835 |
0.582 |
|
| 2021 |
Waheed DE, Schiller J, Stanley M, Franco EL, Poljak M, Kjaer SK, Del Pino M, van der Klis F, Schim van der Loeff MF, Baay M, Van Damme P, Vorsters A. Human papillomavirus vaccination in adults: impact, opportunities and challenges - a meeting report. Bmc Proceedings. 15: 16. PMID 34384438 DOI: 10.1186/s12919-021-00217-4 |
0.429 |
|
| 2021 |
Zola Matuvanga T, Johnson G, Larivière Y, Esanga Longomo E, Matangila J, Maketa V, Lapika B, Mitashi P, Mc Kenna P, De Bie J, Van Geertruyden JP, Van Damme P, Muhindo Mavoko H. Use of Iris Scanning for Biometric Recognition of Healthy Adults Participating in an Ebola Vaccine Trial in the Democratic Republic of the Congo: Mixed Methods Study. Journal of Medical Internet Research. 23: e28573. PMID 34378545 DOI: 10.2196/28573 |
0.442 |
|
| 2021 |
Wahid R, Mercer L, Macadam A, Carlyle S, Stephens L, Martin J, Chumakov K, Laassri M, Petrovskaya S, Smits SL, Stittelaar KJ, Gast C, Weldon WC, Konopka-Anstadt JL, Steven Oberste M, ... Van Damme P, et al. Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses. Npj Vaccines. 6: 94. PMID 34326330 DOI: 10.1038/s41541-021-00355-y |
0.474 |
|
| 2021 |
Khetsuriani N, Mosina L, Van Damme P, Mozalevskis A, Datta S, Tohme RA. Progress Toward Hepatitis B Control - World Health Organization European Region, 2016-2019. Mmwr. Morbidity and Mortality Weekly Report. 70: 1029-1035. PMID 34324482 DOI: 10.15585/mmwr.mm7030a1 |
0.5 |
|
| 2021 |
Geysels D, Van Damme P, Verstrepen W, Bruynseels P, Janssens B, Smits P, Naesens R. SARS-CoV-2 vaccine breakthrough infections among healthcare workers in a large Belgian hospital network. Infection Control and Hospital Epidemiology. 1-2. PMID 34289927 DOI: 10.1017/ice.2021.326 |
0.418 |
|
| 2021 |
Badur S, Öztürk S, Ozakay A, Khalaf M, Saha D, Van Damme P. A review of the experience of childhood hepatitis A vaccination in Saudi Arabia and Turkey: implications for hepatitis A control and prevention in the Middle East and North African region. Human Vaccines & Immunotherapeutics. 1-19. PMID 34213403 DOI: 10.1080/21645515.2021.1920871 |
0.587 |
|
| 2021 |
Ilogu LC, Lugovska O, Vojtek I, Prugnola A, Callegaro A, Mazzilli S, Van Damme P. The intent of students to vaccinate is influenced by cultural factors, peer network, and knowledge about vaccines. Human Vaccines & Immunotherapeutics. 1-9. PMID 34191678 DOI: 10.1080/21645515.2021.1938492 |
0.576 |
|
| 2021 |
Budroni S, Buricchi F, Cavallone A, Bourguignon P, Caubet M, Dewar V, D'Oro U, Finco O, Garçon N, El Idrissi M, Janssens M, Leroux-Roels G, Marchant A, Schwarz T, Van Damme P, et al. Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. Npj Vaccines. 6: 78. PMID 34021167 DOI: 10.1038/s41541-021-00337-0 |
0.379 |
|
| 2021 |
Vesikari T, Langley JM, Segall N, Ward BJ, Cooper C, Poliquin G, Smith B, Gantt S, McElhaney JE, Dionne M, van Damme P, Leroux-Roels I, Leroux-Roels G, Machluf N, Spaans JN, et al. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. The Lancet. Infectious Diseases. PMID 33989539 DOI: 10.1016/S1473-3099(20)30780-5 |
0.614 |
|
| 2021 |
Maertens K, Orije MRP, Herzog SA, Mahieu LM, Hens N, Van Damme P, Leuridan E. Pertussis immunization during pregnancy: assessment of the role of maternal antibodies on immune responses in term and preterm born infants. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 33971009 DOI: 10.1093/cid/ciab424 |
0.328 |
|
| 2021 |
Koc ÖM, De Smedt P, Kremer C, Robaeys G, Van Damme P, Hens N, Almeida J, Falkenberg F, Savelkoul P, Oude Lashof A. Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders: double-blinded, randomised, controlled phase 2 trial. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 33966331 DOI: 10.1111/liv.14939 |
0.584 |
|
| 2021 |
Samyn M, Van Hal G, Vandevijvere H, Van Damme P. The influenza vaccine for nursing and care professionals at emergency services in Flanders. Human Vaccines & Immunotherapeutics. 1-4. PMID 33844618 DOI: 10.1080/21645515.2021.1894062 |
0.547 |
|
| 2021 |
Orije MRP, Larivière Y, Herzog SA, Mahieu LM, Van Damme P, Leuridan E, Maertens K. Breast milk antibody levels in Tdap vaccinated women after preterm delivery. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 33768227 DOI: 10.1093/cid/ciab260 |
0.449 |
|
| 2021 |
Joura EA, Ulied A, Vandermeulen C, Rua Figueroa M, Seppä I, Hernandez Aguado JJ, Ahonen A, Reich O, Virta M, Perino A, Peris Tuser M, Peters K, Origoni M, Raspagliesi F, Tjalma WAA, ... ... van Damme P, et al. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study. Vaccine. PMID 33676783 DOI: 10.1016/j.vaccine.2021.01.074 |
0.392 |
|
| 2021 |
Soentjens P, Berens-Riha N, Van Herrewege Y, Van Damme P, Bottieau E, Ravinetto R. Vaccinating children in high-endemic rabies regions: what are we waiting for? Bmj Global Health. 6. PMID 33568394 DOI: 10.1136/bmjgh-2020-004074 |
0.494 |
|
| 2021 |
Andani A, van Damme P, Bunge EM, Salgado F, van Hoorn RC, Hoet B. One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review. Vaccine. PMID 33526283 DOI: 10.1016/j.vaccine.2021.01.038 |
0.552 |
|
| 2021 |
Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. The New England Journal of Medicine. PMID 33440088 DOI: 10.1056/NEJMoa2034201 |
0.453 |
|
| 2020 |
Brickley EB, Connor RI, Wieland-Alter W, Weiner JA, Ackerman ME, Arita M, Gast C, De Coster I, Van Damme P, Bandyopadhyay AS, Wright PF. Intestinal antibody responses to two novel live attenuated type 2 oral poliovirus vaccines in healthy adults in Belgium. The Journal of Infectious Diseases. PMID 33367918 DOI: 10.1093/infdis/jiaa783 |
0.432 |
|
| 2020 |
Herzog C, Van Herck K, Van Damme P. Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence. Human Vaccines & Immunotherapeutics. 1-24. PMID 33325760 DOI: 10.1080/21645515.2020.1819742 |
0.812 |
|
| 2020 |
Desmet S, Wouters I, Heirstraeten LV, Beutels P, Van Damme P, Malhotra-Kumar S, Maes P, Verhaegen J, Peetermans WE, Lagrou K, Theeten H. In-depth analysis of pneumococcal serotypes in Belgian children (2015-2018): Diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease. Vaccine. PMID 33308889 DOI: 10.1016/j.vaccine.2020.11.044 |
0.525 |
|
| 2020 |
De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, De Smedt P, Aerssens A, Leroux-Roels G, Oberste MS, Konopka-Anstadt JL, Weldon WC, Fix A, Konz J, Wahid R, ... ... Van Damme P, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet (London, England). PMID 33308429 DOI: 10.1016/S0140-6736(20)32541-1 |
0.541 |
|
| 2020 |
Tran TMP, Maertens K, Hoang HTT, Van Damme P, Leuridan E, Hens N. Elucidating the difference in the kinetics of antibody titres of infants in Belgium and Vietnam. Vaccine. PMID 32933790 DOI: 10.1016/J.Vaccine.2020.09.003 |
0.486 |
|
| 2020 |
Wanlapakorn N, Maertens K, Thongmee T, Srimuan D, Thatsanathorn T, Van Damme P, Leuridan E, Poovorawan Y. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers. Vaccine. PMID 32888740 DOI: 10.1016/j.vaccine.2020.08.058 |
0.596 |
|
| 2020 |
Schenk J, Abrams S, Theeten H, Van Damme P, Beutels P, Hens N. Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis. The Lancet. Infectious Diseases. PMID 32888410 DOI: 10.1016/S1473-3099(20)30442-4 |
0.617 |
|
| 2020 |
Pattyn J, Van Keer S, Téblick L, Van Damme P, Vorsters A. Non-invasive Assessment of Vaccine-Induced HPV Antibodies via First-Void Urine. Frontiers in Immunology. 11: 1657. PMID 32849573 DOI: 10.3389/fimmu.2020.01657 |
0.334 |
|
| 2020 |
Dinleyici EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the COVID-19 pandemic. Human Vaccines & Immunotherapeutics. 1-8. PMID 32845739 DOI: 10.1080/21645515.2020.1804776 |
0.558 |
|
| 2020 |
Olsson SE, Restrepo JA, Reina JC, Pitisuttithum P, Ulied A, Varman M, Van Damme P, Moreira ED, Ferris D, Block S, Bautista O, Gallagher N, McCauley J, Luxembourg A. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Research (Amsterdam, Netherlands). 100203. PMID 32659510 DOI: 10.1016/j.pvr.2020.100203 |
0.57 |
|
| 2020 |
Yeh MT, Bujaki E, Dolan PT, Smith M, Wahid R, Konz J, Weiner AJ, Bandyopadhyay AS, Van Damme P, De Coster I, Revets H, Macadam A, Andino R. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host & Microbe. PMID 32330425 DOI: 10.1016/J.Chom.2020.04.003 |
0.55 |
|
| 2020 |
Pattyn J, Panicker G, Willhauck-Fleckenstein M, Van Keer S, Téblick L, Pieters Z, Tjalma WAA, Matheeussen V, Van Damme P, Waterboer T, Unger ER, Vorsters A. Comparison of a VLP-based and GST-L1-based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first-void urine. Journal of Medical Virology. PMID 32266996 DOI: 10.1002/Jmv.25841 |
0.335 |
|
| 2020 |
Beran J, Leroux-Roels G, Van Damme P, de Hoon J, Vandermeulen C, Al-Ibrahim M, Johnson C, Peterson J, Baker S, Seidl C, Dreisbach A, Karsten A, Corsaro B, Henry O, Lattanzi M, et al. Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial. Vaccine. PMID 32169390 DOI: 10.1016/J.Vaccine.2020.02.085 |
0.426 |
|
| 2020 |
Bartholomeus E, De Neuter N, Suls A, Elias G, van der Heijden S, Keersmaekers N, Jansens H, Van Tendeloo V, Beutels P, Laukens K, Ogunjimi B, Mortier G, Meysman P, Van Damme P. Transcriptomic profiling of different responder types in adults after a Priorix® vaccination. Vaccine. PMID 32165045 DOI: 10.1016/j.vaccine.2020.03.004 |
0.505 |
|
| 2020 |
Wouters I, Desmet S, Van Heirstraeten L, Herzog SA, Beutels P, Verhaegen J, Goossens H, Van Damme P, Malhotra-Kumar S, Theeten H, NPcarriage Study Group. How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 25. PMID 32046817 DOI: 10.2807/1560-7917.ES.2020.25.5.1900303 |
0.423 |
|
| 2020 |
Posuwan N, Wanlapakorn N, Vongpunsawad S, Sintusek P, Leuridan E, Van Damme P, Poovorawan Y. Comparison of hepatitis B surface antibody levels induced by the pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine, administered to infants at 2, 4, 6, and 18 months of age, following monovalent hepatitis B vaccination at birth. Vaccine. PMID 31948817 DOI: 10.1016/j.vaccine.2019.12.065 |
0.655 |
|
| 2020 |
Maertens K, Orije MRP, Van Damme P, Leuridan E. Vaccination during pregnancy: current and possible future recommendations. European Journal of Pediatrics. 179: 235-242. PMID 31912233 DOI: 10.1007/s00431-019-03563-w |
0.506 |
|
| 2020 |
Andani A, van Damme P, Bunge EM, Salgado F, van Hoorn RC, Hoet B. 34. Impact of Universal Mass Vaccination Programs of Children Against Hepatitis a with 2-dose and 1-dose Schedules: A Systematic Literature Review Open Forum Infectious Diseases. 7: S17-S18. DOI: 10.1093/ofid/ofaa417.033 |
0.497 |
|
| 2019 |
Orije MRP, Maertens K, Corbière V, Wanlapakorn N, Van Damme P, Leuridan E, Mascart F. The effect of maternal antibodies on the cellular immune response after infant vaccination: A review. Vaccine. PMID 31672332 DOI: 10.1016/j.vaccine.2019.10.025 |
0.432 |
|
| 2019 |
Maltezou HC, Botelho-Nevers E, Brantsæter AB, Carlsson RM, Heininger U, Hübschen JM, Josefsdottir KS, Kassianos G, Kyncl J, Ledda C, Medić S, Nitsch-Osuch A, de Lejarazu RO, Theodoridou M, Van Damme P, et al. Vaccination of healthcare personnel in Europe: Update to current policies. Vaccine. PMID 31623916 DOI: 10.1016/j.vaccine.2019.09.061 |
0.587 |
|
| 2019 |
Vorsters A, Van Damme P, Bosch X. HPV vaccination, are we overlooking additional opportunities to control HPV infection and transmission? International Journal of Infectious Diseases : Ijid : Official Publication of the International Society For Infectious Diseases. PMID 31521851 DOI: 10.1016/j.ijid.2019.09.006 |
0.377 |
|
| 2019 |
Pattyn J, Van Keer S, Tjalma W, Matheeussen V, Van Damme P, Vorsters A. Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. Papillomavirus Research (Amsterdam, Netherlands). 100185. PMID 31494291 DOI: 10.1016/J.Pvr.2019.100185 |
0.367 |
|
| 2019 |
Kauffmann F, Van Damme P, Leroux-Roels G, Vandermeulen C, Berthels N, Beuneu C, Mali S. Clinical trials with GMO-containing vaccines in Europe: Status and regulatory framework. Vaccine. 37: 6144-6153. PMID 31493949 DOI: 10.1016/j.vaccine.2019.08.018 |
0.538 |
|
| 2019 |
Van Damme P, Coster I, Bandyopadhyay AS, Suykens L, Rudelsheim P, Neels P, Oberste MS, Weldon WC, Clemens R, Revets H. Poliopolis: pushing boundaries of scientific innovations for disease eradication. Future Microbiology. PMID 31482728 DOI: 10.2217/Fmb-2019-0196 |
0.603 |
|
| 2019 |
Vorsters A, Bonanni P, Maltezou HC, Yarwood J, Brewer NT, Bosch FX, Hanley S, Cameron R, Franco EL, Arbyn M, Muñoz N, Kojouharova M, Pattyn J, Baay M, Karafillakis E, ... Van Damme P, et al. The role of healthcare providers in HPV vaccination programs - A meeting report. Papillomavirus Research (Amsterdam, Netherlands). 100183. PMID 31476478 DOI: 10.1016/J.Pvr.2019.100183 |
0.396 |
|
| 2019 |
Wanlapakorn N, Maertens K, Vongpunsawad S, Peunpa J, Tran TMP, Hens N, Van Damme P, Thiriard A, Raze D, Locht C, Poovorawan Y, Leuridan E. Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31418814 DOI: 10.1093/Cid/Ciz778 |
0.399 |
|
| 2019 |
Koc Ö, Van Damme P, Busschots D, Bielen R, Forier A, Nevens F, Robaeys G. Acute hepatitis B notification rates in Flanders, Belgium, 2009 to 2017. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 24. PMID 31362809 DOI: 10.2807/1560-7917.ES.2019.24.30.1900064 |
0.312 |
|
| 2019 |
Schim van der Loeff MF, Vorsters A, Marra E, Van Damme P, Hogewoning A. Letter to the editor: female sex workers and HPV vaccine. Human Vaccines & Immunotherapeutics. 1-2. PMID 31348738 DOI: 10.1080/21645515.2019.1643679 |
0.464 |
|
| 2019 |
Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, Suykens L, Oberste MS, Weldon WC, Costa-Clemens SA, Clemens R, Modlin J, Weiner AJ, Macadam AJ, Andino R, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet (London, England). PMID 31174831 DOI: 10.1016/S0140-6736(19)31279-6 |
0.591 |
|
| 2019 |
Van Keer S, Willhauck-Fleckenstein M, Pattyn J, Butt J, Tjalma WAA, Van Ostade X, Hens N, Van Damme P, Waterboer T, Vorsters A. First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions. Journal of Clinical Virology : the Official Publication of the Pan American Society For Clinical Virology. 117: 11-18. PMID 31129514 DOI: 10.1016/J.Jcv.2019.05.004 |
0.353 |
|
| 2019 |
Van Damme P, Dionne M, Leroux-Roels G, Van Der Meeren O, Di Paolo E, Salaun B, Suryakiran P, Folschweiller N. Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults. Journal of Viral Hepatitis. PMID 31087382 DOI: 10.1111/jvh.13125 |
0.607 |
|
| 2019 |
Schim van der Loeff MF, Vorsters A, Marra E, Van Damme P, Hogewoning A. Should female sex workers be offered HPV vaccination? Human Vaccines & Immunotherapeutics. 1-5. PMID 31063078 DOI: 10.1080/21645515.2019.1602432 |
0.463 |
|
| 2019 |
Koc ÖM, Hens N, Bielen R, Van Damme P, Robaeys G. Hepatitis B virus prevalence and risk factors in hard-to-reach Turkish population living in Belgium: A protocol for screening. Medicine. 98: e15412. PMID 31045797 DOI: 10.1097/Md.0000000000015412 |
0.306 |
|
| 2019 |
Van Damme P, Leroux-Roels G, Vandermeulen C, De Ryck I, Tasciotti A, Dozot M, Moraschini L, Testa M, Arora AK. Safety and immunogenicity of non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine. Vaccine. PMID 31029515 DOI: 10.1016/j.vaccine.2019.04.041 |
0.53 |
|
| 2019 |
Keersmaekers N, Ogunjimi B, Van Damme P, Beutels P, Hens N. An ODE-based mixed modelling approach for B- and T-cell dynamics induced by Varicella-Zoster Virus vaccines in adults shows higher T-cell proliferation with Shingrix than with Varilrix. Vaccine. PMID 30975567 DOI: 10.1016/j.vaccine.2019.03.075 |
0.523 |
|
| 2019 |
Wouters I, Desmet S, Van Heirstraeten L, Blaizot S, Verhaegen J, Van Damme P, Malhotra-Kumar S, Theeten H. Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium. Vaccine. 37: 1080-1086. PMID 30665775 DOI: 10.1016/j.vaccine.2018.12.068 |
0.545 |
|
| 2019 |
Van Mulder TJS, Withanage K, Beyers KCL, Vankerckhoven VVJ, Theeten H, Van Damme P. Immunogenicity and safety of intradermal delivery of hepatitis B booster vaccine using the novel drug delivery device VAX-ID™. Vaccine. 37: 581-586. PMID 30587432 DOI: 10.1016/j.vaccine.2018.12.016 |
0.489 |
|
| 2019 |
Soentjens P, De Koninck K, Tsoumanis A, Herssens N, Van Den Bossche D, Terryn S, Van Gucht S, Van Damme P, Van Herrewege Y, Bottieau E. Comparative Immunogenicity and Safety Trial of 2 Different Schedules of Single-visit Intradermal Rabies Postexposure Vaccination. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 69: 797-804. PMID 30566636 DOI: 10.1093/cid/ciy983 |
0.585 |
|
| 2019 |
Soentjens P, Andries P, Aerssens A, Tsoumanis A, Ravinetto R, Heuninckx W, van Loen H, Brochier B, Van Gucht S, Van Damme P, Van Herrewege Y, Bottieau E. Preexposure Intradermal Rabies Vaccination: A Noninferiority Trial in Healthy Adults on Shortening the Vaccination Schedule From 28 to 7 Days. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 68: 607-614. PMID 29939243 DOI: 10.1093/cid/ciy513 |
0.591 |
|
| 2019 |
Vesikari T, Langley JM, Langley JM, Smith B, van Damme P, Leroux-Roels I, Leroux-Roels G, Spaans J, Machluf N, Yassin-Rajkumar B, Anderson D, Popovic V, Diaz-Mitoma F. LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT) Open Forum Infectious Diseases. 6: S998-S998. DOI: 10.1093/Ofid/Ofz415.2496 |
0.54 |
|
| 2018 |
Bartholomeus E, De Neuter N, Meysman P, Suls A, Keersmaekers N, Elias G, Jansens H, Hens N, Smits E, Van Tendeloo V, Beutels P, Van Damme P, Ogunjimi B, Laukens K, Mortier G. Transcriptome profiling in blood before and after hepatitis B vaccination shows significant differences in gene expression between responders and non-responders. Vaccine. PMID 30205979 DOI: 10.1016/J.Vaccine.2018.09.001 |
0.603 |
|
| 2018 |
Pham TT, Le HM, Nguyen DT, Maertens K, Leuridan E, Theeten H, Hendrickx G, Van Damme P. Assessment of the timely administration of the hepatitis B and BCG birth dose and the primary infant vaccination schedule in 2015-2016 in the Mekong Delta, Viet Nam. Vaccine. PMID 30121141 DOI: 10.1016/j.vaccine.2018.08.002 |
0.581 |
|
| 2018 |
Whitford K, Liu B, Micallef J, Yin JK, Macartney K, Van Damme P, Kaldor JM. Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis. Bulletin of the World Health Organization. 96: 484-497. PMID 29962551 DOI: 10.2471/BLT.17.205153 |
0.382 |
|
| 2018 |
Braeckman T, Theeten H, Roelants M, Blaizot S, Hoppenbrouwers K, Maertens K, Van Damme P, Vandermeulen C. Can Flanders resist the measles outbreak? Assessing vaccination coverage in different age groups among Flemish residents. Epidemiology and Infection. 1-5. PMID 29716667 DOI: 10.1017/S0950268818000985 |
0.569 |
|
| 2018 |
Maertens K, Braeckman T, Blaizot S, Theeten H, Roelants M, Hoppenbrouwers K, Leuridan E, Van Damme P, Vandermeulen C. Coverage of recommended vaccines during pregnancy in Flanders, Belgium. Fairly good but can we do better? Vaccine. 36: 2687-2693. PMID 29627238 DOI: 10.1016/j.vaccine.2018.03.033 |
0.495 |
|
| 2018 |
Petry KU, Bollaerts K, Bonanni P, Stanley M, Drury R, Joura E, Kjaer SK, Meijer CJLM, Riethmuller D, Soubeyrand B, Van Damme P, Bosch X. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. Human Vaccines & Immunotherapeutics. 1-23. PMID 29553886 DOI: 10.1080/21645515.2018.1450125 |
0.392 |
|
| 2018 |
Wanlapakorn N, Maertens K, Chaithongwongwatthana S, Srimuan D, Suratannon N, Vongpunsawad S, Mai Phuong Tran T, Hens N, Van Damme P, Locht C, Poovorawan Y, Leuridan E. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women. Vaccine. PMID 29426663 DOI: 10.1016/J.Vaccine.2018.01.059 |
0.52 |
|
| 2018 |
Beran J, Lickliter JD, Schwarz TF, Johnson C, Chu L, Domachowske JB, Van Damme P, Withanage K, Fissette LA, David MP, Maleux K, Schmidt AC, Picciolato M, Dieussaert I. Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in non-pregnant women: results from two phase II trials. The Journal of Infectious Diseases. PMID 29401325 DOI: 10.1093/Infdis/Jiy065 |
0.461 |
|
| 2018 |
Wouters I, Van Heirstraeten L, Desmet S, Blaizot S, Verhaegen J, Goossens H, Van Damme P, Malhotra-Kumar S, Theeten H. Nasopharyngeal s. pneumoniae carriage and density in Belgian infants after 9 years of pneumococcal conjugate vaccine programme. Vaccine. 36: 15-22. PMID 29180027 DOI: 10.1016/j.vaccine.2017.11.052 |
0.459 |
|
| 2018 |
Leroux-Roels G, Cramer JP, Mendelman PM, Sherwood J, Clemens R, Aerssens A, De Coster I, Borkowski A, Baehner F, Van Damme P. Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. The Journal of Infectious Diseases. 217: 597-607. PMID 29140444 DOI: 10.1093/infdis/jix572 |
0.512 |
|
| 2017 |
Moreira ED, Giuliano AR, de Hoon J, Iversen OE, Joura EA, Restrepo J, Van Damme P, Vandermeulen C, Ellison MC, Krick A, Shields C, Heiles B, Luxembourg A. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age. Human Vaccines & Immunotherapeutics. 1-8. PMID 29211620 DOI: 10.1080/21645515.2017.1403700 |
0.592 |
|
| 2017 |
Vorsters A, Arbyn M, Baay M, Bosch X, de Sanjosé S, Hanley S, Karafillakis E, Lopalco PL, Pollock KG, Yarwood J, Van Damme P. Overcoming barriers in HPV vaccination and screening programs. Papillomavirus Research (Amsterdam, Netherlands). 4: 45-53. PMID 29179869 DOI: 10.1016/j.pvr.2017.07.001 |
0.492 |
|
| 2017 |
Strezova A, Godeaux O, Aggarwal N, Leroux-Roels G, Lopez-Fauqued M, Van Damme P, Vanden Abeele C, Vastiau I, Heineman TC, Lal H. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. Vaccine. PMID 29079101 DOI: 10.1016/j.vaccine.2017.10.017 |
0.54 |
|
| 2017 |
Harrington L, Van Damme P, Vandermeulen C, Mali S. Recruitment barriers for prophylactic vaccine trials: A study in Belgium. Vaccine. PMID 29074202 DOI: 10.1016/j.vaccine.2017.10.041 |
0.44 |
|
| 2017 |
Sesay S, Brzostek J, Meyer I, Donazzolo Y, Leroux-Roels G, Rouzier R, Astruc B, Szymanski H, Toursarkissian N, Vandermeulen C, Kowalska E, Van Damme P, Salamand C, Pepin S. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: a phase III randomized, double-blind clinical trial. Human Vaccines & Immunotherapeutics. 0. PMID 28968138 DOI: 10.1080/21645515.2017.1384106 |
0.447 |
|
| 2017 |
Leroux-Roels G, Van Damme P, Haazen W, Shakib S, Caubet M, Aris E, Devaster JM, Peeters M. Erratum to "Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults" [Vaccine 34 (2016) 3156-3163]. Vaccine. PMID 28882439 DOI: 10.1016/j.vaccine.2017.08.076 |
0.537 |
|
| 2017 |
Maertens K, Tran TMP, Hens N, Van Damme P, Leuridan E. Effect of Prepregnancy Pertussis Vaccination in Young Infants. The Journal of Infectious Diseases. 215: 1855-1861. PMID 28863468 DOI: 10.1093/Infdis/Jix176 |
0.519 |
|
| 2017 |
Petersen LK, Restrepo J, Moreira ED, Iversen OE, Pitisuttithum P, Van Damme P, Joura EA, Olsson SE, Ferris D, Block S, Giuliano AR, Bosch X, Pils S, Cuzick J, Garland SM, et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials. Papillomavirus Research (Amsterdam, Netherlands). 3: 105-115. PMID 28720442 DOI: 10.1016/J.Pvr.2017.03.002 |
0.455 |
|
| 2017 |
Maertens K, Burbidge P, Van Damme P, Goldblatt D, Leuridan E. Pneumococcal Immune Response in Infants Whose Mothers Received Tdap Vaccination During Pregnancy. The Pediatric Infectious Disease Journal. PMID 28399054 DOI: 10.1097/INF.0000000000001601 |
0.485 |
|
| 2017 |
Van Damme P, Leroux-Roels G, Suryakiran P, Folschweiller N, Van Der Meeren O. Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine. Human Vaccines & Immunotherapeutics. 1-9. PMID 28281907 DOI: 10.1080/21645515.2016.1274473 |
0.631 |
|
| 2017 |
Caboré RN, Maertens K, Dobly A, Leuridan E, Van Damme P, Huygen K. Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium. Virulence. 0. PMID 28277900 DOI: 10.1080/21505594.2017.1296998 |
0.541 |
|
| 2016 |
Arbyn M, Vanden Broeck D, Bogers J, Van Damme P, Temmerman M, Weyers S. Enrolment of young women attending cervical cancer screening to survey effectiveness of HPV vaccination. Cancer Epidemiology. PMID 27847177 DOI: 10.1016/j.canep.2016.10.017 |
0.322 |
|
| 2016 |
Maertens K, Hoang TT, Nguyen TD, Caboré RN, Duong TH, Huygen K, Hens N, Van Damme P, Dang DA, Leuridan E. The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 63: S197-S204. PMID 27838673 DOI: 10.1093/Cid/Ciw551 |
0.559 |
|
| 2016 |
Sobanjo-Ter Meulen A, Duclos P, McIntyre P, Lewis KD, Van Damme P, O'Brien KL, Klugman KP. Assessing the Evidence for Maternal Pertussis Immunization: A Report From the Bill & Melinda Gates Foundation Symposium on Pertussis Infant Disease Burden in Low- and Lower-Middle-Income Countries. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 63: S123-S133. PMID 27838664 DOI: 10.1093/Cid/Ciw530 |
0.35 |
|
| 2016 |
Lazarus R, Kelly S, Snape MD, Vandermeulen C, Voysey M, Hoppenbrouwers K, Hens A, Van Damme P, Pepin S, Leroux-Roels I, Leroux-Roels G, Pollard AJ. Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. Plos One. 11: e0165384. PMID 27814377 DOI: 10.1371/journal.pone.0165384 |
0.603 |
|
| 2016 |
Maertens K, Braeckman T, Top G, Van Damme P, Leuridan E. Maternal pertussis and influenza immunization coverage and attitude of health care workers towards these recommendations in Flanders, Belgium. Vaccine. PMID 27742214 DOI: 10.1016/j.vaccine.2016.09.055 |
0.524 |
|
| 2016 |
Levin Y, Kochba E, Shukarev G, Rusch S, Herrera-Taracena G, van Damme P. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. Vaccine. PMID 27667332 DOI: 10.1016/j.vaccine.2016.09.008 |
0.549 |
|
| 2016 |
Philip RK, Shapiro M, Paterson P, Glismann S, Van Damme P. Is It Time For Vaccination To "Go Viral"? The Pediatric Infectious Disease Journal. PMID 27626913 DOI: 10.1097/INF.0000000000001321 |
0.564 |
|
| 2016 |
Mayorga O, Bühler S, Jaeger VK, Bally S, Hatz C, Frösner G, Protzer U, Van Damme P, Egger M, Herzog C. Single dose hepatitis A immunisation: 7·5 year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response. The Journal of Infectious Diseases. PMID 27601623 DOI: 10.1093/infdis/jiw411 |
0.596 |
|
| 2016 |
Van Mulder TJ, de Koeijer M, Theeten H, Willems D, Van Damme P, Demolder M, De Meyer G, Beyers KC, Vankerckhoven V. High frequency ultrasound to assess skin thickness in healthy adults. Vaccine. PMID 27496276 DOI: 10.1016/j.vaccine.2016.07.039 |
0.576 |
|
| 2016 |
Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M. Corrigendum to "Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines" [Vaccine 34 (2016) 757-761]. Vaccine. PMID 27461456 DOI: 10.1016/j.vaccine.2016.07.035 |
0.551 |
|
| 2016 |
Van Damme P, Stanley M. Re: Letter to the Editor: P. van Damme et al., Vaccine 34 (2016) 757-761, as a reply to Ryser et al's letter in Vaccine. Vaccine. 34: 4272. PMID 27452650 DOI: 10.1016/j.vaccine.2016.06.068 |
0.386 |
|
| 2016 |
Moreira ED, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, et al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. PMID 27422279 DOI: 10.1542/Peds.2015-4387 |
0.421 |
|
| 2016 |
Sabbe M, Berger N, Blommaert A, Ogunjimi B, Grammens T, Callens M, Van Herck K, Beutels P, Van Damme P, Bilcke J. Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. Euro Surveillance : Bulletin EuropéEn Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 21. PMID 27418466 DOI: 10.2807/1560-7917.Es.2016.21.27.30273 |
0.797 |
|
| 2016 |
Van Damme P, Meijer CJ, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, Baudin M. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. PMID 27354258 DOI: 10.1016/j.vaccine.2016.06.056 |
0.445 |
|
| 2016 |
Kane MA, Roudot-Thoraval F, Guerin N, Papaevangelou V, Van Damme P. Global progress in the control of viral hepatitis and acceptable delay in Hepatitis B immunization. Human Vaccines & Immunotherapeutics. 1-4. PMID 27261211 DOI: 10.1080/21645515.2016.1177689 |
0.441 |
|
| 2016 |
Maertens K, Caboré RN, Huygen K, Vermeiren S, Hens N, Van Damme P, Leuridan E. Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. Vaccine. PMID 27142328 DOI: 10.1016/J.Vaccine.2016.04.066 |
0.602 |
|
| 2016 |
Esposito S, Bonanni P, Maggi S, Tan L, Ansaldi F, Lopalco PL, Dagan R, Michel JP, van Damme P, Gaillat J, Prymula R, Vesikari T, Mussini C, Frank U, Osterhaus A, et al. Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Human Vaccines & Immunotherapeutics. 1-18. PMID 27135390 DOI: 10.1080/21645515.2016.1150396 |
0.549 |
|
| 2016 |
Leroux-Roels G, Van Damme P, Haazen W, Shakib S, Caubet M, Aris E, Devaster JM, Peeters M. Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. Vaccine. PMID 27133877 DOI: 10.1016/j.vaccine.2016.04.051 |
0.531 |
|
| 2016 |
Theeten H, Mathei C, Peeters K, Ogunjimi B, Goossens H, Ieven M, Van Damme P, Cools N. Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly. Viral Immunology. PMID 27002465 DOI: 10.1089/Vim.2015.0071 |
0.389 |
|
| 2016 |
Franceschi S, Chantal Umulisa M, Tshomo U, Gheit T, Baussano I, Tenet V, Tshokey T, Gatera M, Ngabo F, Van Damme P, Snijders PJ, Tommasino M, Vorsters A, Clifford GM. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. International Journal of Cancer. 139: 518-26. PMID 26991686 DOI: 10.1002/ijc.30092 |
0.468 |
|
| 2016 |
Van Damme P. Long-term Protection After Hepatitis B Vaccine. The Journal of Infectious Diseases. 214: 1-3. PMID 26802140 DOI: 10.1093/infdis/jiv750 |
0.584 |
|
| 2016 |
Van Damme P, Bonanni P, Bosch FX, Joura E, Krüger Kjaer S, Meijer CJ, Petry KU, Soubeyrand B, Verstraeten T, Stanley M. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines. Vaccine. 34: 757-61. PMID 26772631 DOI: 10.1016/j.vaccine.2015.12.063 |
0.594 |
|
| 2016 |
Maertens K, Caboré RN, Huygen K, Hens N, Van Damme P, Leuridan E. Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study. Vaccine. 34: 142-50. PMID 26592142 DOI: 10.1016/J.Vaccine.2015.10.100 |
0.522 |
|
| 2015 |
Ha HT, Leuridan E, Maertens K, Nguyen TD, Hens N, Vu NH, Caboré RN, Duong HT, Huygen K, Van Damme P, Anh DD. Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy. Vaccine. PMID 26529073 DOI: 10.1016/J.Vaccine.2015.10.098 |
0.571 |
|
| 2015 |
Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World Journal of Hepatology. 7: 2127-32. PMID 26328023 DOI: 10.4254/wjh.v7.i18.2127 |
0.532 |
|
| 2015 |
Lefevere E, Theeten H, Hens N, De Smet F, Top G, Van Damme P. From non school-based, co-payment to school-based, free Human Papillomavirus vaccination in Flanders (Belgium): a retrospective cohort study describing vaccination coverage, age-specific coverage and socio-economic inequalities. Vaccine. 33: 5188-95. PMID 26254978 DOI: 10.1016/J.Vaccine.2015.07.088 |
0.539 |
|
| 2015 |
Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine. 33: 5723-7. PMID 26190091 DOI: 10.1016/J.Vaccine.2015.07.008 |
0.79 |
|
| 2015 |
Huygen K, Caboré RN, Maertens K, Van Damme P, Leuridan E. Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and nonpregnant women. Vaccine. 33: 4117-23. PMID 26187257 DOI: 10.1016/j.vaccine.2015.06.108 |
0.587 |
|
| 2015 |
Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, Huang LM, Kim DS, Pitisuttithum P, Chen J, Christiano S, Maansson R, Moeller E, Sun X, Vuocolo S, et al. Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics. PMID 26101366 DOI: 10.1542/peds.2014-3745 |
0.503 |
|
| 2015 |
De Coster I, Fournie X, Faure C, Ziani E, Nicolas L, Soubeyrand B, Van Damme P. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 33: 3976-82. PMID 26092310 DOI: 10.1016/j.vaccine.2015.06.030 |
0.553 |
|
| 2015 |
Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Kjeld Petersen L, Tran C, Thomas S, Luxembourg A, Baudin M. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil®in 9-15-Year-Old Girls. The Pediatric Infectious Disease Journal. PMID 26090572 DOI: 10.1097/INF.0000000000000773 |
0.524 |
|
| 2015 |
Nguyen TD, Dang AD, Van Damme P, Nguyen CV, Duong HT, Goossens H, Theeten H, Leuridan E. Coverage of the expanded program on immunization in Vietnam: Results from 2 cluster surveys and routine reports. Human Vaccines & Immunotherapeutics. 11: 1526-33. PMID 25970593 DOI: 10.1080/21645515.2015.1032487 |
0.47 |
|
| 2015 |
Vesikari T, Van Damme P, Giaquinto C, Dagan R, Guarino A, Szajewska H, Usonis V. European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe: update 2014. The Pediatric Infectious Disease Journal. 34: 635-43. PMID 25860532 DOI: 10.1097/INF.0000000000000683 |
0.575 |
|
| 2015 |
Kosalaraksa P, Mehlsen J, Vesikari T, Forstén A, Helm K, Van Damme P, Joura EA, Ciprero K, Maansson R, Luxembourg A, Sobanjo-ter Meulen A. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. The Pediatric Infectious Disease Journal. 34: 627-34. PMID 25831420 DOI: 10.1097/INF.0000000000000694 |
0.592 |
|
| 2015 |
De Schutter S, Maertens K, Baerts L, De Meester I, Van Damme P, Leuridan E. Quantification of vaccine-induced antipertussis toxin secretory IgA antibodies in breast milk: comparison of different vaccination strategies in women. The Pediatric Infectious Disease Journal. 34: e149-52. PMID 25719454 DOI: 10.1097/INF.0000000000000675 |
0.44 |
|
| 2015 |
Vorsters A, Van Keer S, Van Damme P. The use of urine in the follow-up of HPV vaccine trials. Human Vaccines & Immunotherapeutics. 11: 350-2. PMID 25664398 DOI: 10.4161/21645515.2014.995058 |
0.343 |
|
| 2015 |
Vandermeulen C, Theeten H, Rathi N, Kuriyakose S, Han HH, Sokal E, Hoppenbrouwers K, Van Damme P. Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium. Vaccine. 33: 3026-34. PMID 25613716 DOI: 10.1016/j.vaccine.2014.10.049 |
0.602 |
|
| 2015 |
Hens N, Abrams S, Santermans E, Theeten H, Goeyvaerts N, Lernout T, Leuridan E, Van Kerckhove K, Goossens H, Van Damme P, Beutels P. Assessing the risk of measles resurgence in a highly vaccinated population: Belgium anno 2013 Euro Surveillance : Bulletin EuropéEn Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 20. PMID 25613653 DOI: 10.2807/1560-7917.Es2015.20.1.20998 |
0.485 |
|
| 2015 |
Van Herck K, Hens A, De Coster I, Vertruyen A, Tolboom J, Sarnecki M, Van Damme P. Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis A vaccine. The Pediatric Infectious Disease Journal. 34: e85-91. PMID 25389920 DOI: 10.1097/INF.0000000000000616 |
0.806 |
|
| 2015 |
Kevorkyan A, Teoharov P, Lernout T, Petrova N, Raycheva R, Ivanov I, van Damme P, Kojouharova M. Prevalence of HBV and HCV among outpatients in the Plovdiv region of Bulgaria, 2010-2011. Journal of Medical Virology. 87: 401-6. PMID 25163778 DOI: 10.1002/jmv.24065 |
0.481 |
|
| 2014 |
Trang NV, Braeckman T, Lernout T, Hau VT, Anh le TK, Luan le T, Van Damme P, Anh DD. Prevalence of rotavirus antibodies in breast milk and inhibitory effects to rotavirus vaccines. Human Vaccines & Immunotherapeutics. 10: 3681-7. PMID 25668672 DOI: 10.4161/21645515.2014.980204 |
0.375 |
|
| 2014 |
Van Mulder TJ, Verwulgen S, Beyers KC, Scheelen L, Elseviers MM, Van Damme P, Vankerckhoven V. Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects. Human Vaccines & Immunotherapeutics. 10: 3746-53. PMID 25531808 DOI: 10.4161/21645515.2014.979655 |
0.372 |
|
| 2014 |
Verhaegen J, Flamaing J, De Backer W, Delaere B, Van Herck K, Surmont F, Van Laethem Y, Van Damme P, Peetermans W. Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009-2011. Euro Surveillance : Bulletin EuropéEn Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 19: 14-22. PMID 25138972 DOI: 10.2807/1560-7917.ES2014.19.31.20869 |
0.621 |
|
| 2014 |
Van den Bergh JM, Guerti K, Willemen Y, Lion E, Cools N, Goossens H, Vorsters A, Van Tendeloo VF, Anguille S, Van Damme P, Smits EL. HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells. Journal of Cellular and Molecular Medicine. 18: 1372-80. PMID 24979331 DOI: 10.1111/Jcmm.12284 |
0.356 |
|
| 2014 |
FitzSimons D, Hendrickx G, Lernout T, Badur S, Vorsters A, Van Damme P. Incentives and barriers regarding immunization against influenza and hepatitis of health care workers. Vaccine. 32: 4849-54. PMID 24968151 DOI: 10.1016/j.vaccine.2014.06.072 |
0.486 |
|
| 2014 |
Braeckman T, Theeten H, Lernout T, Hens N, Roelants M, Hoppenbrouwers K, Van Damme P. Rotavirus vaccination coverage and adherence to recommended age among infants in flanders (Belgium) in 2012 Eurosurveillance. 19. PMID 24871757 DOI: 10.2807/1560-7917.Es2014.19.20.20806 |
0.611 |
|
| 2014 |
Heldens J, Hulskotte E, Voeten T, Breedveld B, Verweij P, van Duijnhoven W, Rudenko L, van Damme P, van den Bosch H. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers. Vaccine. 32: 5118-24. PMID 24858566 DOI: 10.1016/j.vaccine.2014.05.030 |
0.416 |
|
| 2014 |
Lernout T, Hendrickx G, Vorsters A, Mosina L, Emiroglu N, Van Damme P. A cohesive European policy for hepatitis B vaccination, are we there yet? Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 19-24. PMID 24829936 DOI: 10.1111/1469-0691.12535 |
0.658 |
|
| 2014 |
Lernout T, Theeten H, Leuridan E, Van Damme P. Do vaccines save lives? Yes they do! Acta MéDica Portuguesa. 27: 160-2. PMID 24813482 |
0.587 |
|
| 2014 |
Parez N, Giaquinto C, Du Roure C, Martinon-Torres F, Spoulou V, Van Damme P, Vesikari T. Rotavirus vaccination in Europe: drivers and barriers. The Lancet. Infectious Diseases. 14: 416-25. PMID 24758998 DOI: 10.1016/S1473-3099(14)70035-0 |
0.594 |
|
| 2014 |
Van Damme P, Leroux-Roels G, Simon P, Foidart JM, Donders G, Hoppenbrouwers K, Levin M, Tibaldi F, Poncelet S, Moris P, Dessy F, Giannini SL, Descamps D, Dubin G. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Vaccine. 32: 3694-705. PMID 24674663 DOI: 10.1016/j.vaccine.2014.03.040 |
0.404 |
|
| 2014 |
Maertens K, De Schutter S, Braeckman T, Baerts L, Van Damme P, De Meester I, Leuridan E. Breastfeeding after maternal immunisation during pregnancy: providing immunological protection to the newborn: a review. Vaccine. 32: 1786-92. PMID 24530929 DOI: 10.1016/j.vaccine.2014.01.083 |
0.387 |
|
| 2014 |
Hens N, Habteab Ghebretinsae A, Hardt K, Van Damme P, Van Herck K. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine. 32: 1507-13. PMID 24508042 DOI: 10.1016/J.Vaccine.2013.10.088 |
0.765 |
|
| 2014 |
Braeckman T, Lernout T, Top G, Paeps A, Roelants M, Hoppenbrouwers K, Van Damme P, Theeten H. Assessing vaccination coverage in infants, survey studies versus the Flemish immunisation register: achieving the best of both worlds. Vaccine. 32: 345-9. PMID 24269616 DOI: 10.1016/j.vaccine.2013.11.041 |
0.467 |
|
| 2014 |
Lernout T, Theeten H, Hens N, Braeckman T, Roelants M, Hoppenbrouwers K, Van Damme P. Timeliness of infant vaccination and factors related with delay in Flanders, Belgium. Vaccine. 32: 284-9. PMID 24252698 DOI: 10.1016/J.Vaccine.2013.10.084 |
0.594 |
|
| 2014 |
Theeten H, Hutse V, Hoppenbrouwers K, Beutels P, Van Damme P. Universal hepatitis B vaccination in Belgium: Impact on serological markers 3 and 7 years after implementation Epidemiology and Infection. 142: 251-261. PMID 23689103 DOI: 10.1017/S0950268813001064 |
0.648 |
|
| 2014 |
De Coster I, Fournie X, Ziani E, Soubeyrand B, Van Damme P. O-147a Assessment Of Preparation Time With Fully Liquid Versus Reconstituted Paediatric Hexavalent Vaccines. A Time And Motion Study Archives of Disease in Childhood. 99: A80.2-A81. DOI: 10.1136/ARCHDISCHILD-2014-307384.214 |
0.339 |
|
| 2013 |
Abu-Elyazeed RR, Heineman T, Dubin G, Fourneau M, Leroux-Roels I, Leroux-Roels G, Richardus JH, Ostergaard L, Diez-Domingo J, Poder A, Van Damme P, Romanowski B, Blatter M, Silfverdal SA, et al. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial. Vaccine. 31: 6136-43. PMID 23850416 DOI: 10.1016/j.vaccine.2013.06.081 |
0.581 |
|
| 2013 |
Van Damme P, Leuridan E, Hendrickx G, Vorsters A, Theeten H, Leino T, Salminen M, Kuusi M. Should Europe have a universal hepatitis B vaccination programme? Bmj (Clinical Research Ed.). 347: f4057. PMID 23843546 |
0.622 |
|
| 2013 |
Ogunjimi B, Van Damme P, Beutels P. Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review. Plos One. 8: e66485. PMID 23805224 DOI: 10.1371/journal.pone.0066485 |
0.47 |
|
| 2013 |
Leuridan E, Hoang TT, Dang DA, Van Damme P. Pertussis vaccination and pregnancy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 57: 471-2. PMID 23580733 DOI: 10.1093/cid/cit217 |
0.508 |
|
| 2013 |
Van Damme P, Kafeja F, Bambure V, Hanon E, Moris P, Roman F, Gillard P. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older. Human Vaccines & Immunotherapeutics. 9: 1512-22. PMID 23571166 DOI: 10.4161/hv.24504 |
0.572 |
|
| 2013 |
Derhovanessian E, Theeten H, Hähnel K, Van Damme P, Cools N, Pawelec G. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine. 31: 685-90. PMID 23196209 DOI: 10.1016/J.Vaccine.2012.11.041 |
0.392 |
|
| 2013 |
FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. Vaccine. 31: 584-90. PMID 23142301 DOI: 10.1016/j.vaccine.2012.10.101 |
0.652 |
|
| 2013 |
Teoharov P, Kevorkyan A, Petrova N, Baltadzhiev I, Van Damme P. Immune memory and immune response in children from Bulgaria 5-15 years after primary hepatitis B vaccination. The Pediatric Infectious Disease Journal. 32: 51-3. PMID 22914584 DOI: 10.1097/INF.0b013e31826f354e |
0.519 |
|
| 2013 |
Neels P, van Damme P, van Ranst M, Dogné JM. Human papillomavirus vaccines: understanding the benefit-risk. Annals of Medicine. 45: 203-5. PMID 22758373 DOI: 10.3109/07853890.2012.700117 |
0.494 |
|
| 2012 |
Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane MA. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases. Vaccine. 30: F1-11. PMID 23199951 DOI: 10.1016/j.vaccine.2012.05.090 |
0.399 |
|
| 2012 |
Hendrickx G, Vorsters A, Van Damme P. Advances in hepatitis immunization (A, B, E): public health policy and novel vaccine delivery. Current Opinion in Infectious Diseases. 25: 578-83. PMID 22907280 DOI: 10.1097/QCO.0b013e328357e65c |
0.615 |
|
| 2012 |
Braeckman T, Van Herck K, Meyer N, Pirçon JY, Soriano-Gabarró M, Heylen E, Zeller M, Azou M, Capiau H, De Koster J, Maernoudt AS, Raes M, Verdonck L, Verghote M, Vergison A, ... ... Van Damme P, et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. Bmj (Clinical Research Ed.). 345: e4752. PMID 22875947 DOI: 10.1136/bmj.e4752 |
0.739 |
|
| 2012 |
Luyten J, Van de Sande S, de Schrijver K, Van Damme P, Beutels P. Cost-effectiveness of hepatitis A vaccination for adults in Belgium. Vaccine. 30: 6070-80. PMID 22858555 DOI: 10.1016/j.vaccine.2012.07.049 |
0.586 |
|
| 2012 |
Leuridan E, Sabbe M, Van Damme P. Measles outbreak in Europe: susceptibility of infants too young to be immunized. Vaccine. 30: 5905-13. PMID 22841972 DOI: 10.1016/j.vaccine.2012.07.035 |
0.425 |
|
| 2012 |
Braeckman T, Van Herck K, Jilg W, Bauer T, Van Damme P. Two decades of hepatitis B vaccination in mentally retarded patients: effectiveness, antibody persistence and duration of immune memory. Vaccine. 30: 4757-61. PMID 22652400 DOI: 10.1016/j.vaccine.2012.05.044 |
0.779 |
|
| 2012 |
Ogunjimi B, Van Tendeloo V, Van Damme P, Beutels P. What counts in cytometric analysis to document vaccine immunogenicity? Human Vaccines & Immunotherapeutics. 8: 499-500. PMID 22370519 DOI: 10.4161/hv.18855 |
0.422 |
|
| 2012 |
Goeyvaerts N, Hens N, Theeten H, Aerts M, Van Damme P, Beutels P. Estimating vaccination coverage for the trivalent measles-mumps-rubella vaccine from trivariate serological data. Statistics in Medicine. 31: 1432-49. PMID 22362265 DOI: 10.1002/Sim.4481 |
0.546 |
|
| 2012 |
Van Herck K, Crasta PD, Messier M, Hardt K, Van Damme P. Seventeen-year antibody persistence in adults primed with two doses of an inactivated hepatitis A vaccine. Human Vaccines & Immunotherapeutics. 8: 323-7. PMID 22327499 DOI: 10.4161/hv.18617 |
0.765 |
|
| 2012 |
Bilcke J, Ogunjimi B, Marais C, De Smet F, Callens M, Callaert K, Van Kerschaver E, Ramet J, Van Damme P, Beutels P. The health and economic burden of chickenpox and herpes zoster in Belgium Epidemiology and Infection. 140: 2096-2109. PMID 22230041 DOI: 10.1017/S0950268811002640 |
0.335 |
|
| 2012 |
Van Damme P, Leroux-Roels G, Crasta P, Messier M, Jacquet JM, Van Herck K. Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine. Journal of Medical Virology. 84: 11-7. PMID 22052690 DOI: 10.1002/jmv.22264 |
0.813 |
|
| 2012 |
Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine. 30: 2795-800. PMID 21964056 DOI: 10.1016/J.Vaccine.2011.09.079 |
0.599 |
|
| 2011 |
Aichinger G, Ehrlich HJ, Aaskov JG, Fritsch S, Thomasser C, Draxler W, Wolzt M, Müller M, Pinl F, Van Damme P, Hens A, Levy J, Portsmouth D, Holzer G, Kistner O, et al. Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial. Vaccine. 29: 9376-84. PMID 22001875 DOI: 10.1016/j.vaccine.2011.09.125 |
0.472 |
|
| 2011 |
van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, Rondini S, Micoli F, Qasim Khan RM, Marchetti E, Di Cioccio V, Saul A, Martin LB, Podda A. Safety, immunogenicity and dose ranging of a new Vi-CRMâ‚₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. Plos One. 6: e25398. PMID 21980445 DOI: 10.1371/journal.pone.0025398 |
0.61 |
|
| 2011 |
Van Herck K, Jacquet JM, Van Damme P. Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. Journal of Medical Virology. 83: 1885-91. PMID 21915861 DOI: 10.1002/jmv.22200 |
0.812 |
|
| 2011 |
Lefevere E, Hens N, Theeten H, Van den Bosch K, Beutels P, De Smet F, Van Damme P. Like mother, like daughter? Mother's history of cervical cancer screening and daughter's Human Papillomavirus vaccine uptake in Flanders (Belgium). Vaccine. 29: 8390-6. PMID 21856360 DOI: 10.1016/J.Vaccine.2011.08.039 |
0.342 |
|
| 2011 |
Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok AS, Manns M, ... ... van Damme P, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. Journal of Viral Hepatitis. 18: 1-16. PMID 21824223 DOI: 10.1111/j.1365-2893.2011.01499.x |
0.345 |
|
| 2011 |
Giaquinto C, Dominiak-Felden G, Van Damme P, Myint TTH, Maldonado YA, Spoulou V, Mast TC, Staat MA. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries Human Vaccines. 7: 734-748. PMID 21734466 DOI: 10.4161/hv.7.7.15511 |
0.598 |
|
| 2011 |
Van Damme P, McIntyre P, Grimprel E, Kuriyakose S, Jacquet JM, Hardt K, Messier M, Van Der Meeren O. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine. 29: 5932-9. PMID 21718738 DOI: 10.1016/j.vaccine.2011.06.049 |
0.571 |
|
| 2011 |
Lefevere E, Hens N, De Smet F, Van Damme P. Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007-2009: a Cox regression model. Bmc Public Health. 11: 470. PMID 21672202 DOI: 10.1186/1471-2458-11-470 |
0.477 |
|
| 2011 |
Plotkin S, Leuridan E, Van Damme P. Hepatitis B and the Need for a Booster Dose Clinical Infectious Diseases. 53: 68-75. PMID 21653306 DOI: 10.1093/cid/cir270 |
0.482 |
|
| 2011 |
Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, Tozzi AE, Van Damme P. Rationale for pertussis booster vaccination throughout life in Europe. The Lancet. Infectious Diseases. 11: 557-70. PMID 21600850 DOI: 10.1016/S1473-3099(11)70007-X |
0.554 |
|
| 2011 |
Hanquet G, Ducoffre G, Vergison A, Neels P, Sabbe M, Van Damme P, Van Herck K. Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine. 29: 4698-703. PMID 21571023 DOI: 10.1016/j.vaccine.2011.04.098 |
0.791 |
|
| 2011 |
Chlibek R, von Sonnenburg F, Van Damme P, Smetana J, Tichy P, Gunapalaiah B, Leyssen M, Jacquet JM. Antibody persistence and immune memory 4 years post-vaccination with combined hepatitis A and B vaccine in adults aged over 40 years. Journal of Travel Medicine. 18: 145-8. PMID 21366801 DOI: 10.1111/j.1708-8305.2010.00499.x |
0.667 |
|
| 2011 |
van Damme P, Kafeja F, Van Der Wielen M, Leyssen M, Jacquet JM. Long-term immunogenicity and immune memory after two doses of the adult formulation of a combined hepatitis A and B vaccine in children 1 to 11 years of age. The Pediatric Infectious Disease Journal. 30: 703-5. PMID 21346683 DOI: 10.1097/INF.0b013e3182138296 |
0.535 |
|
| 2011 |
Leuridan E, Hens N, Peeters N, de Witte L, Van der Meeren O, Van Damme P. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. The Pediatric Infectious Disease Journal. 30: 608-10. PMID 21206396 DOI: 10.1097/Inf.0B013E3182093814 |
0.432 |
|
| 2011 |
Romano' L, Paladini S, Van Damme P, Zanetti AR. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. 43: S2-7. PMID 21195368 DOI: 10.1016/S1590-8658(10)60685-8 |
0.565 |
|
| 2011 |
Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, Van Damme P. Rotavirus vaccines in Belgium: policy and impact. The Pediatric Infectious Disease Journal. 30: S21-4. PMID 21183836 DOI: 10.1097/INF.0b013e3181fefc51 |
0.798 |
|
| 2011 |
Hanquet G, Van Damme P, Brasseur D, De Cuyper X, Gregor S, Holmberg M, Martin R, Molnár Z, Pompa MG, Snacken R, van der Sande M, Van Ranst M, Wirtz A, Neels P. Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010). Vaccine. 29: 370-7. PMID 21075164 DOI: 10.1016/j.vaccine.2010.10.079 |
0.565 |
|
| 2011 |
Asnong C, Van Herck K, Lernout T, Theeten H, Van Damme P. Lessons learned from a measles outbreak in Antwerp, Belgium 2007-2008. The Pediatric Infectious Disease Journal. 30: 343-5. PMID 20924311 DOI: 10.1097/INF.0b013e3181fbf5b7 |
0.783 |
|
| 2011 |
Theeten H, Hutse V, Hens N, Yavuz Y, Hoppenbrouwers K, Beutels P, Vranckx R, Van Damme P. Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium Epidemiology and Infection. 139: 494-504. PMID 20587123 DOI: 10.1017/S0950268810001536 |
0.381 |
|
| 2010 |
Van Damme P, Moiseeva A, Marichev I, Kervyn AD, Booy R, Kuriyakose S, Brockway A, Ng SP, Leyssen M, Jacquet JM. Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study. Bmc Infectious Diseases. 10: 357. PMID 21171982 DOI: 10.1186/1471-2334-10-357 |
0.563 |
|
| 2010 |
Arbyn M, Simoens C, Van Damme P, Scharpantgen A, Meijer CJLM, Beutels P. Introduction of human papillomavirus vaccination in Belgium, Luxembourg and The Netherlands Gynecologic and Obstetric Investigation. 70: 224-232. PMID 21051840 DOI: 10.1159/000314010 |
0.516 |
|
| 2010 |
Vankerckhoven V, Van Damme P. Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines. Expert Opinion On Drug Delivery. 7: 1109-25. PMID 20716021 DOI: 10.1517/17425247.2010.507668 |
0.617 |
|
| 2010 |
Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 51: 668-77. PMID 20687838 DOI: 10.1086/655830 |
0.464 |
|
| 2010 |
Itzler R, Koch G, Matson DO, Gothefors L, Van Damme P, Dinubile MJ, Heaton PM. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). Bmc Pediatrics. 10: 42. PMID 20540778 DOI: 10.1186/1471-2431-10-42 |
0.41 |
|
| 2010 |
Van Damme P, Arnou R, Kafeja F, Fiquet A, Richard P, Thomas S, Meghlaoui G, Samson SI, Ledesma E. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. Bmc Infectious Diseases. 10: 134. PMID 20504306 DOI: 10.1186/1471-2334-10-134 |
0.61 |
|
| 2010 |
Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: Longitudinal study Bmj (Online). 340: 1123. PMID 20483946 DOI: 10.1136/Bmj.C1626 |
0.395 |
|
| 2010 |
Van Damme P, Zanetti AR, Shouval D, Van Herck K. Strategies for global prevention of hepatitis B virus infection. Advances in Experimental Medicine and Biology. 659: 175-88. PMID 20204764 DOI: 10.1007/978-1-4419-0981-7_14 |
0.625 |
|
| 2010 |
Vorsters A, Tack S, Hendrickx G, Vladimirova N, Bonanni P, Pistol A, Metlicar T, Pasquin MJ, Mayer MA, Aronsson B, Heijbel H, Van Damme P. A summer school on vaccinology: Responding to identified gaps in pre-service immunisation training of future health care workers. Vaccine. 28: 2053-9. PMID 20038430 DOI: 10.1016/j.vaccine.2009.12.033 |
0.324 |
|
| 2010 |
Vesikari T, Van Damme P, Lindblad N, Pfletschinger U, Radley D, Ryan D, Vuocolo S, Haupt RM, Guris D. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. The Pediatric Infectious Disease Journal. 29: 314-8. PMID 19952980 DOI: 10.1097/INF.0b013e3181c177fb |
0.544 |
|
| 2010 |
FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis A and E: update on prevention and epidemiology. Vaccine. 28: 583-8. PMID 19925903 DOI: 10.1016/j.vaccine.2009.10.136 |
0.368 |
|
| 2009 |
Matthijnssens J, Bilcke J, Ciarlet M, Martella V, Bányai K, Rahman M, Zeller M, Beutels P, Van Damme P, Van Ranst M. Rotavirus disease and vaccination: impact on genotype diversity. Future Microbiology. 4: 1303-16. PMID 19995190 DOI: 10.2217/Fmb.09.96 |
0.531 |
|
| 2009 |
Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, Goveia MG. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine. 28: 345-51. PMID 19879226 DOI: 10.1016/j.vaccine.2009.10.041 |
0.414 |
|
| 2009 |
Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 27: 7304-12. PMID 19849996 DOI: 10.1016/j.vaccine.2009.10.033 |
0.613 |
|
| 2009 |
Leroux-Roels I, Van der Wielen M, Kafeja F, Vandermeulen C, Lazarus R, Snape MD, John T, Carre C, Nougarede N, Pepin S, Leroux-Roels G, Hoppenbrouwers K, Pollard AJ, Van Damme P. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine. 27: 6918-25. PMID 19761837 DOI: 10.1016/j.vaccine.2009.08.110 |
0.565 |
|
| 2009 |
Van Damme P, von Sonnenburg F, Hatz C, Hoet B, Lefevre I, Leyssen M. Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults. Journal of Medical Virology. 81: 1710-5. PMID 19697416 DOI: 10.1002/jmv.21568 |
0.655 |
|
| 2009 |
Theeten H, Vandermeulen C, Roelants M, Hoppenbrouwers K, Depoorter AM, Van Damme P. Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium. Acta Paediatrica (Oslo, Norway : 1992). 98: 1307-12. PMID 19432835 DOI: 10.1111/j.1651-2227.2009.01331.x |
0.615 |
|
| 2009 |
Vorsters A, Van Herck K, Van Damme P. The clock is running, ... Vaccine. 27: 2905-6. PMID 19428900 DOI: 10.1016/j.vaccine.2009.01.124 |
0.533 |
|
| 2009 |
Theeten H, Hens N, Aerts M, Vandermeulen C, Roelants M, Hoppenbrouwers K, Van Damme P, Beutels P. Common attitudes about concomitant vaccine injections for infants and adolescents in Flanders, Belgium. Vaccine. 27: 1964-9. PMID 19368778 DOI: 10.1016/J.Vaccine.2009.01.096 |
0.517 |
|
| 2009 |
David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecologic Oncology. 115: S1-6. PMID 19217149 DOI: 10.1016/j.ygyno.2009.01.011 |
0.753 |
|
| 2009 |
Ciarlet M, He S, Lai S, Petrecz M, Yuan G, Liu GF, Mikviman E, Heaton PM, Panzer F, Rose T, Koller DY, Van Damme P, Schödel F. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. The Pediatric Infectious Disease Journal. 28: 177-81. PMID 19209092 DOI: 10.1097/INF.0b013e31818c0161 |
0.622 |
|
| 2009 |
De Hert M, Wampers M, Van Eyck D, Peuskens J, Franic T, Vidovic D, Van Herck K, Van Damme P. Prevalence of HIV and hepatitis C infection among patients with schizophrenia. Schizophrenia Research. 108: 307-8. PMID 19091513 DOI: 10.1016/j.schres.2008.11.008 |
0.574 |
|
| 2009 |
Theeten H, Hens N, Aerts M, Vandermeulen C, Roelants M, Hoppenbrouwers K, Van Damme P, Beutels P. Caregivers' willingness to pay to reduce the number of vaccine injections in infants. The Pediatric Infectious Disease Journal. 28: 61-3. PMID 19034063 DOI: 10.1097/Inf.0B013E318184Eea3 |
0.404 |
|
| 2009 |
Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care'' disease impact in Belgium. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 29: 33-50. PMID 18948433 DOI: 10.1177/0272989X08324955 |
0.319 |
|
| 2009 |
Van Damme P, Minervini G, Liss CL, McCarson B, Vesikari T, Boslego JW, Bhuyan PK. Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. Human Vaccines. 5: 92-7. PMID 18690015 DOI: 10.4161/hv.5.2.6587 |
0.599 |
|
| 2008 |
Van Herck K, Vorsters A, Van Damme P. Prevention of viral hepatitis (B and C) reassessed. Best Practice & Research. Clinical Gastroenterology. 22: 1009-29. PMID 19187864 DOI: 10.1016/j.bpg.2008.11.008 |
0.758 |
|
| 2008 |
Nardone A, Anastassopoulou CG, Theeten H, Kriz B, Davidkin I, Thierfelder W, O'Flanagan D, Bruzzone B, Mossong J, Boot HJ, Butur D, Slaciková M, Panait ML, Hellenbrand W, DE Melker H, ... ... VAN Damme P, et al. A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiology and Infection. 137: 961-9. PMID 19102797 DOI: 10.1017/S0950268808001672 |
0.542 |
|
| 2008 |
Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine. 27: 454-9. PMID 19022318 DOI: 10.1016/j.vaccine.2008.10.077 |
0.562 |
|
| 2008 |
Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 26: 6266-73. PMID 18848855 DOI: 10.1016/j.vaccine.2008.09.056 |
0.571 |
|
| 2008 |
Hendrickx G, Van Herck K, Vorsters A, Wiersma S, Shapiro C, Andrus JK, Ropero AM, Shouval D, Ward W, Van Damme P. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. Journal of Viral Hepatitis. 15: 1-15. PMID 18837827 DOI: 10.1111/j.1365-2893.2008.01022.x |
0.766 |
|
| 2008 |
Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine. 26: 6529-41. PMID 18805453 DOI: 10.1016/j.vaccine.2008.08.067 |
0.528 |
|
| 2008 |
Van Herck K, Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. The Pediatric Infectious Disease Journal. 27: 861-9. PMID 18776823 DOI: 10.1097/INF.0b013e318173966f |
0.782 |
|
| 2008 |
FitzSimons D, François G, De Carli G, Shouval D, Prüss-Ustün A, Puro V, Williams I, Lavanchy D, De Schryver A, Kopka A, Ncube F, Ippolito G, Van Damme P. Hepatitis B virus, hepatitis C virus and other blood-borne infections in healthcare workers: guidelines for prevention and management in industrialised countries. Occupational and Environmental Medicine. 65: 446-51. PMID 18562683 DOI: 10.1136/oem.2006.032334 |
0.326 |
|
| 2008 |
Vesikari T, Van Damme P, Giaquinto C, Gray J, Mrukowicz J, Dagan R, Guarino A, Szajewska H, Usonis V. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary. Journal of Pediatric Gastroenterology and Nutrition. 46: 615-8. PMID 18493224 DOI: 10.1097/MPG.0b013e31816e213a |
0.469 |
|
| 2008 |
Vesikari T, Van Damme P, Giaquinto C, Gray J, Mrukowicz J, Dagan R, Guarino A, Szajewska H, Usonis V. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. Journal of Pediatric Gastroenterology and Nutrition. S38-48. PMID 18460971 DOI: 10.1097/MPG.0b013e31816f7a10 |
0.47 |
|
| 2008 |
Vandermeulen C, Roelants M, Theeten H, Depoorter AM, Van Damme P, Hoppenbrouwers K. Vaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinants. Pediatrics. 121: e428-34. PMID 18310163 DOI: 10.1542/peds.2007-1415 |
0.521 |
|
| 2008 |
Vandermeulen C, Roelants M, Theeten H, Van Damme P, Hoppenbrouwers K. Vaccination coverage and sociodemographic determinants of measles-mumps-rubella vaccination in three different age groups. European Journal of Pediatrics. 167: 1161-8. PMID 18204860 DOI: 10.1007/s00431-007-0652-3 |
0.457 |
|
| 2008 |
Hollinger FB, Bell B, Levy-Bruhl D, Shouval D, Wiersma S, Van Damme P. Hepatitis A and B vaccination and public health. Journal of Viral Hepatitis. 1-5. PMID 17958635 DOI: 10.1111/j.1365-2893.2007.00924.x |
0.587 |
|
| 2008 |
Theeten H, Rümke H, Hoppener FJ, Vilatimó R, Narejos S, Van Damme P, Hoet B. Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. Current Medical Research and Opinion. 23: 2729-39. PMID 17897485 DOI: 10.1185/03007X233034 |
0.631 |
|
| 2008 |
Hens N, Aerts M, Shkedy Z, Kung'u Kimani P, Kojouhorova M, Van Damme P, Beutels P. Estimating the impact of vaccination using age-time-dependent incidence rates of hepatitis B Epidemiology and Infection. 136: 341-351. PMID 17506920 DOI: 10.1017/S0950268807008692 |
0.421 |
|
| 2007 |
Van Herck K, Leuridan E, Van Damme P. Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance. Sexually Transmitted Infections. 83: 426-32. PMID 17911142 DOI: 10.1136/sti.2006.022111 |
0.809 |
|
| 2007 |
Van Der Wielen M, Vertruyen A, Froesner G, Ibáñez R, Hunt M, Herzog C, Van Damme P. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years. The Pediatric Infectious Disease Journal. 26: 705-10. PMID 17848882 DOI: 10.1097/INF.0b013e31806215c8 |
0.634 |
|
| 2007 |
Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine. 25: 6296-304. PMID 17629601 DOI: 10.1016/J.VACCINE.2007.06.020 |
0.574 |
|
| 2007 |
Schmitt HJ, Booy R, Aston R, Van Damme P, Schumacher RF, Campins M, Rodrigo C, Heikkinen T, Weil-Olivier C, Finn A, Olcén P, Fedson D, Peltola H. How to optimise the coverage rate of infant and adult immunisations in Europe. Bmc Medicine. 5: 11. PMID 17535430 DOI: 10.1186/1741-7015-5-11 |
0.497 |
|
| 2007 |
Theeten H, Hens N, Vandermeulen C, Depoorter AM, Roelants M, Aerts M, Hoppenbrouwers K, Van Damme P. Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. Vaccine. 25: 4940-8. PMID 17524528 DOI: 10.1016/J.Vaccine.2007.03.032 |
0.625 |
|
| 2007 |
Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Medicine and Infectious Disease. 5: 171-5. PMID 17448944 DOI: 10.1016/j.tmaid.2006.07.003 |
0.785 |
|
| 2007 |
Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML, Rendi-Wagner P, Steffen R, Van Damme P. The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: Review and consensus statement on hepatitis A and B vaccination Journal of Travel Medicine. 14: 181-187. PMID 17437475 DOI: 10.1111/j.1708-8305.2007.00123.x |
0.494 |
|
| 2007 |
Kafatos G, Anastassopoulou C, Nardone A, Andrews N, Barbara C, Boot HJ, Butur D, Davidkin I, Gelb D, Griskevicius A, Hesketh L, Icardi G, Jones L, Kra-Oz Z, Miller E, ... ... Van Damme P, et al. The European Sero-Epidemiology Network 2: standardization of assay results for hepatitis B virus. Journal of Viral Hepatitis. 14: 260-8. PMID 17381718 DOI: 10.1111/j.1365-2893.2006.00789.x |
0.483 |
|
| 2007 |
Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Medicine and Infectious Disease. 5: 79-84. PMID 17298912 DOI: 10.1016/j.tmaid.2006.04.004 |
0.825 |
|
| 2007 |
Beutels P, Van Damme P. Effectiveness of seven-valent pneumococcal conjugate vaccine. Lancet (London, England). 369: 460; author reply 46. PMID 17292755 DOI: 10.1016/S0140-6736(07)60223-2 |
0.613 |
|
| 2007 |
Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine. 25: 2194-212. PMID 17267077 DOI: 10.1016/j.vaccine.2006.11.032 |
0.547 |
|
| 2007 |
Wouters K, Leuridan E, Van Herck K, Van Ardenne N, Roelofs I, Mak R, Prévost C, Guérin P, Denis B, Van Damme P. Compliance and immunogenicity of two hepatitis B vaccination schedules in sex workers in Belgium. Vaccine. 25: 1893-900. PMID 17239492 DOI: 10.1016/j.vaccine.2006.09.073 |
0.788 |
|
| 2007 |
Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006). Vaccine. 25: 1355-67. PMID 17208339 DOI: 10.1016/j.vaccine.2006.10.034 |
0.549 |
|
| 2006 |
Heron L, Selnikova O, Moiseieva A, Van Damme P, van der Wielen M, Levie K, Hoet B, Stoffel M. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial. Vaccine. 25: 2817-22. PMID 17276552 DOI: 10.1016/J.VACCINE.2006.12.021 |
0.317 |
|
| 2006 |
Van Damme P, Van der Wielen M, Ansaldi F, Desgrandchamps D, Domingo JD, Sanchez FG, Gray J, Haditsch M, Johansen K, Lorgelly P, Lorrot M, Parez N, Reschke V, Rose M. Rotavirus vaccines: considerations for successful implementation in Europe. The Lancet. Infectious Diseases. 6: 805-12. PMID 17123900 DOI: 10.1016/S1473-3099(06)70657-0 |
0.612 |
|
| 2006 |
Wright TC, Van Damme P, Schmitt HJ, Meheus A. Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine. 24: S3/122-31. PMID 16949999 DOI: 10.1016/j.vaccine.2006.05.118 |
0.596 |
|
| 2006 |
Van der Wielen M, Van Damme P, Chlibek R, Smetana J, von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine. 24: 5509-15. PMID 16725234 DOI: 10.1016/j.vaccine.2006.04.016 |
0.653 |
|
| 2006 |
Peetermans WE, Van de Vyver N, Van Laethem Y, Van Damme P, Thiry N, Trefois P, Geerts P, Schetgen M, Peleman R, Swennen B, Verhaegen J. Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: a Belgian consensus report. Acta Clinica Belgica. 60: 329-37. PMID 16502593 DOI: 10.1179/acb.2005.050 |
0.569 |
|
| 2006 |
Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. The New England Journal of Medicine. 354: 23-33. PMID 16394299 DOI: 10.1056/Nejmoa052664 |
0.45 |
|
| 2005 |
Thiry N, Beutels P, Van Damme P. Economic evaluations of pneumococcal vaccination strategies in adults. A summary of the results Acta Clinica Belgica. 60: 338-344. PMID 16502594 DOI: 10.1179/acb.2005.051 |
0.579 |
|
| 2005 |
François G, Duclos P, Margolis H, Lavanchy D, Siegrist CA, Meheus A, Lambert PH, Emiroğlu N, Badur S, Van Damme P. Vaccine safety controversies and the future of vaccination programs. The Pediatric Infectious Disease Journal. 24: 953-61. PMID 16282928 DOI: 10.1097/01.inf.0000183853.16113.a6 |
0.656 |
|
| 2005 |
Van Herck K, Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Review of Vaccines. 4: 459-71. PMID 16117704 DOI: 10.1586/14760584.4.4.459 |
0.813 |
|
| 2005 |
Fitzsimons D, François G, Alpers K, Radun D, Hallauer J, Jilg W, Gerlich W, Rombo L, Blystad H, Nøkleby H, van Damme P. Prevention of viral hepatitis in the Nordic countries and Germany. Scandinavian Journal of Infectious Diseases. 37: 549-60. PMID 16099768 DOI: 10.1080/00365540510043284 |
0.509 |
|
| 2005 |
De Schrijver K, Maes I, Van Damme P, Tersago J, Moës E, Van Ranst M. An outbreak of nosocomial hepatitis B virus infection in a nursing home for the elderly in Antwerp (Belgium). Acta Clinica Belgica. 60: 63-9. PMID 16082990 DOI: 10.1179/acb.2005.012 |
0.392 |
|
| 2005 |
Van Damme P, Van Herck K. Effect of hepatitis A vaccination programs. Jama. 294: 246-8. PMID 16014600 DOI: 10.1001/jama.294.2.246 |
0.779 |
|
| 2005 |
Malfroot A, Adam G, Ciofu O, Döring G, Knoop C, Lang AB, Van Damme P, Dab I, Bush A. Immunisation in the current management of cystic fibrosis patients Journal of Cystic Fibrosis. 4: 77-87. PMID 15978534 DOI: 10.1016/J.Jcf.2004.10.003 |
0.582 |
|
| 2005 |
Prikazsky V, Leroux-Roels G, Van Damme P, Safary A, Colau B, Duchene M. Comparative pre-clinical and clinical experience with oral polio vaccine produced on MRC-5 cells or on primary monkey kidney cells. Vaccine. 23: 4219-27. PMID 15936120 DOI: 10.1016/J.VACCINE.2005.04.002 |
0.54 |
|
| 2005 |
Theeten H, Van Damme P, Hoppenbrouwers K, Vandermeulen C, Leback E, Sokal EM, Wolter J, Schuerman L. Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine. 23: 1515-21. PMID 15670888 DOI: 10.1016/J.VACCINE.2004.08.002 |
0.587 |
|
| 2004 |
Van Damme PA, Van Herck K, Banatvala JE. Do we need hepatitis A booster vaccinations? Journal of Travel Medicine. 11: 179-80. PMID 15710060 DOI: 10.2310/7060.2004.18479 |
0.819 |
|
| 2004 |
Nothdurft HD, Zuckerman J, Stoffel M, Dieussaert I, Van Damme P. Accelerated vaccination schedules provide protection against hepatitis A and B in last-minute travelers Journal of Travel Medicine. 11: 260-262. PMID 15541232 DOI: 10.2310/7060.2004.19013 |
0.624 |
|
| 2004 |
Thiry N, Beutels P, Tancredi F, Romanò L, Zanetti A, Bonanni P, Gabutti G, Van Damme P. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine. 22: 3546-62. PMID 15315834 DOI: 10.1016/j.vaccine.2004.03.043 |
0.445 |
|
| 2004 |
Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Review of Vaccines. 3: 249-67. PMID 15176942 DOI: 10.1586/14760584.3.3.249 |
0.812 |
|
| 2004 |
Van Herck K, Van Damme P. Hepatitis A vaccine. The New England Journal of Medicine. 350: 2211-2; author reply. PMID 15152071 DOI: 10.1056/NEJM200405203502121 |
0.818 |
|
| 2004 |
Van Herck K, Castelli F, Zuckerman J, Nothdurft H, Van Damme P, Dahlgren AL, Gargalianos P, Lopéz-Vélez R, Overbosch D, Caumes E, Walker E, Gisler S, Steffen R. Knowledge, Attitudes and Practices in Travel-related Infectious Diseases: The European Airport Survey Journal of Travel Medicine. 11: 3-8. PMID 14769280 DOI: 10.2310/7060.2004.13609 |
0.559 |
|
| 2004 |
De Schryver A, De Gendt K, François G, Van Damme P, Meheus A. Hepatitis B surface antigenaemia following vaccination with a combined vaccine against hepatitis A and B Journal of Viral Hepatitis. 11: 88-90. PMID 14738563 DOI: 10.1046/j.1365-2893.2003.00473.x |
0.654 |
|
| 2004 |
Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. Journal of Medical Virology. 72: 194-6. PMID 14695659 DOI: 10.1002/jmv.10574 |
0.748 |
|
| 2004 |
Van Damme P, Burgess M. Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults. Vaccine. 22: 305-8. PMID 14670310 DOI: 10.1016/J.VACCINE.2003.08.012 |
0.604 |
|
| 2004 |
Van Damme P, Van Herck K, Van der Wielen M. Combined hepatitis A and B vaccine in elderly. Vaccine. 22: 303-4. PMID 14670309 |
0.803 |
|
| 2004 |
Van Damme P. Long-term protection after hepatitis A and B vaccination: an update. Acta Gastro-Enterologica Belgica. 66: 247-9. PMID 14618958 |
0.585 |
|
| 2003 |
Zuckerman JN, Van Damme P, Van Herck K, Löscher T. Vaccination options for last-minute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide. Travel Medicine and Infectious Disease. 1: 219-26. PMID 17291921 DOI: 10.1016/j.tmaid.2003.10.001 |
0.813 |
|
| 2003 |
Beutels P, Van Doorslaer E, Van Damme P, Hall J. Methodological issues and new developments in the economic evaluation of vaccines Expert Review of Vaccines. 2: 649-660. PMID 14711326 DOI: 10.1586/14760584.2.5.649 |
0.51 |
|
| 2003 |
André F, Van Damme P, Safary A, Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Review of Vaccines. 1: 9-23. PMID 12908508 DOI: 10.1586/14760584.1.1.9 |
0.649 |
|
| 2003 |
Connor BA, Van Herck K, Van Damme P. Rapid protection and vaccination against hepatitis A for travellers. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 17: 19-21. PMID 12785874 |
0.816 |
|
| 2003 |
Van der Wielen M, Van Damme P, Van Herck K, Schlegel-Haueter S, Siegrist CA. Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium). Vaccine. 21: 2412-7. PMID 12744872 |
0.689 |
|
| 2003 |
Mak R, Traen A, Claeyssens M, Van Renterghem L, Leroux-Roels G, Van Damme P. Hepatitis B vaccination for sex workers: do outreach programmes perform better? Sexually Transmitted Infections. 79: 157-9. PMID 12690142 DOI: 10.1136/sti.79.2.157 |
0.58 |
|
| 2003 |
Van Herck K, Zuckerman J, Castelli F, Van Damme P, Walker E, Steffen R. Travelers' knowledge, attitudes, and practices on prevention of infectious diseases: results from a pilot study. Journal of Travel Medicine. 10: 75-8. PMID 12650648 |
0.562 |
|
| 2003 |
FitzSimons D, François G, Emiroğlu N, Van Damme P. Combined hepatitis B vaccines. Vaccine. 21: 1310-6. PMID 12615425 DOI: 10.1016/S0264-410X(02)00636-9 |
0.627 |
|
| 2003 |
Schmitt HJ, Booy R, Weil-Olivier C, Van Damme P, Cohen R, Peltola H. Child vaccination policies in Europe: a report from the Summits of Independent European Vaccination Experts. The Lancet. Infectious Diseases. 3: 103-8. PMID 12560196 DOI: 10.1016/S1473-3099(03)00519-X |
0.601 |
|
| 2003 |
Van Damme P, Banatvala JE. Vaccine induced protection against hepatitis B. Bmj (Clinical Research Ed.). 326: 105. PMID 12521983 DOI: 10.1136/BMJ.326.7380.105 |
0.619 |
|
| 2003 |
Thiry N, Beutels P, Van Damme P, Van Doorslaer E. Economic evaluations of varicella vaccination programmes: A review of the literature Pharmacoeconomics. 21: 13-38. PMID 12484801 DOI: 10.2165/00019053-200321010-00002 |
0.599 |
|
| 2003 |
François G, Hallauer J, Van Damme P. Hepatitis B vaccination: how to reach risk groups. Vaccine. 21: 1-4. PMID 12443655 DOI: 10.1016/S0264-410X(02)00440-1 |
0.503 |
|
| 2002 |
Beutels P, Van Damme P, Van Casteren V, Gay NJ, De Schrijver K, Meheus A. The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: The case of measles in Flanders (Belgium) Vaccine. 20: 3551-3559. PMID 12297401 DOI: 10.1016/S0264-410X(02)00335-3 |
0.491 |
|
| 2002 |
Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. Journal of Medical Virology. 67: 433-9. PMID 12116040 DOI: 10.1002/JMV.10091 |
0.621 |
|
| 2002 |
Desombere I, Van der Wielen M, Van Damme P, Stoffel M, De Clercq N, Goilav C, Leroux-Roels G. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine. 20: 2597-602. PMID 12057618 DOI: 10.1016/S0264-410X(02)00150-0 |
0.642 |
|
| 2002 |
Steimle D, Aston R, Van Damme P. Immunisation information for parents. Nursing Standard (Royal College of Nursing (Great Britain) : 1987). 16: 40-4. PMID 11974705 DOI: 10.7748/ns2002.04.16.29.40.c3178 |
0.428 |
|
| 2002 |
FitzSimons D, Van Damme P, Emiroglu N, Godal T, Kane M, Malyavin A, Margolis H, Meheus A. Strengthening immunization systems and introduction of hepatitis B vaccine in central and eastern Europe and the Newly Independent States Vaccine. 20: 1475-1479. PMID 11858851 DOI: 10.1016/S0264-410X(01)00504-7 |
0.533 |
|
| 2002 |
Swennen B, Van Damme P, Vellinga A, Coppieters Y, Depoorter AM. Analysis of factors influencing vaccine uptake: perspectives from Belgium. Vaccine. S5-7; discussion S1. PMID 11587800 DOI: 10.1016/S0264-410X(01)00307-3 |
0.482 |
|
| 2001 |
Van Damme P, Van der Wielen M. Combining hepatitis A and B vaccination in children and adolescents. Vaccine. 19: 2407-12. PMID 11257370 DOI: 10.1016/s0264-410x(00)00464-3 |
0.639 |
|
| 2001 |
Van Damme P. Hepatitis B: vaccination programmes in Europe--an update. Vaccine. 19: 2375-9. PMID 11257363 DOI: 10.1016/s0264-410x(00)00457-6 |
0.577 |
|
| 2001 |
Renard D, Bruckers L, Molenberghs G, Vellinga A, Van Damme P. Repeated-measures models to evaluate a hepatitis B vaccination programme. Statistics in Medicine. 20: 951-63. PMID 11252015 DOI: 10.1002/Sim.699 |
0.623 |
|
| 2001 |
Beran J, Beutels M, Levie K, Van Damme P, Dieussaert I, Gillet M, Van Hoecke C, Tornieporth N. A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. Journal of Travel Medicine. 7: 246-52. PMID 11231208 DOI: 10.2310/7060.2000.00073 |
0.643 |
|
| 2001 |
Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. Journal of Medical Virology. 63: 1-7. PMID 11130881 DOI: 10.1002/1096-9071(200101)63:1<1::AID-JMV1000>3.0.CO;2-U |
0.431 |
|
| 2001 |
Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 19: 877-85. PMID 11115711 DOI: 10.1016/S0264-410X(00)00224-3 |
0.519 |
|
| 2001 |
Michiels B, Avonts D, van Damme P, van Royen P, Denkens J. Hepatitis B vaccination among GPs in Flanders, Belgium in 1999 European Journal of General Practice. 7: 77-78. DOI: 10.3109/13814780109048794 |
0.588 |
|
| 2000 |
Van Der Wielen M, Van Damme P, Collard F. A two dose schedule for combined hepatitis A and hepatitis B vaccination in children ages one to eleven years. The Pediatric Infectious Disease Journal. 19: 848-53. PMID 11001108 DOI: 10.1097/00006454-200009000-00008 |
0.553 |
|
| 2000 |
Beutels P, Musabaev EI, Van Damme P, Yasin T. The disease burden of hepatitis B in Uzbekistan Journal of Infection. 40: 234-241. PMID 10908017 DOI: 10.1053/jinf.1998.0666 |
0.43 |
|
| 2000 |
Van der Wielen M, Van Damme P, Joossens E, François G, Meurice F, Ramalho A. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine. 18: 2075-82. PMID 10715521 DOI: 10.1016/S0264-410X(99)00568-X |
0.618 |
|
| 2000 |
Vellinga A, Van Damme P, Joossens E, Goossens H. Response to diphtheria booster vaccination in healthy adults: Vaccine trial British Medical Journal. 320: 217. PMID 10642229 DOI: 10.1136/bmj.320.7229.217 |
0.592 |
|
| 2000 |
Van Herck K, Beutels P, Van Damme P, Beutels M, Van Den Dries J, Briantais P, Vidor E. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines Journal of Medical Virology. 60: 1-7. PMID 10568755 DOI: 10.1002/(SICI)1096-9071(200001)60:1<1::AID-JMV1>3.0.CO;2-H |
0.772 |
|
| 1999 |
Van Herck K, Van Damme P, Collard F, Thoelen S. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years. Scandinavian Journal of Gastroenterology. 34: 1236-40. PMID 10636072 DOI: 10.1080/003655299750024760 |
0.772 |
|
| 1999 |
Vellinga A, Van Damme P, Meheus A. Hepatitis B and C in institutions for individuals with intellectual disability Journal of Intellectual Disability Research. 43: 445-453. PMID 10622359 DOI: 10.1046/j.1365-2788.1999.00222.x |
0.474 |
|
| 1999 |
Frey S, Dagan R, Ashur Y, Chen XQ, Ibarra J, Kollaritsch H, Mazur MH, Poland GA, Reisinger K, Walter E, Van Damme P, Braconier JH, Uhnoo I, Wahl M, Blatter MM, et al. Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. The Journal of Infectious Diseases. 180: 2018-22. PMID 10558961 DOI: 10.1086/315119 |
0.643 |
|
| 1999 |
Thoelen S, Van Damme P, Leentvaar-Kuypers A, Leroux-Roels G, Bruguera M, Frei PC, Bakasenas V, Safary A. The first combined vaccine against hepatitis A and B: an overview. Vaccine. 17: 1657-62. PMID 10194819 DOI: 10.1016/S0264-410X(98)00421-6 |
0.662 |
|
| 1999 |
Vellinga A, Van Damme P, Weyler JJ, Vranckx R, Meheus A. Hepatitis B vaccination in mentally retarded: Effectiveness after 11 years Vaccine. 17: 602-606. PMID 10075168 DOI: 10.1016/S0264-410X(98)00240-0 |
0.581 |
|
| 1999 |
Halsey NA, Duclos P, Van Damme P, Margolis H. Hepatitis B vaccine and central nervous system demyelinating diseases Pediatric Infectious Disease Journal. 18: 23-24. PMID 9951975 DOI: 10.1097/00006454-199901000-00007 |
0.576 |
|
| 1999 |
Van Damme P, Verwimp G. From Cannes 1993 to the present. Vaccine. S3-6. PMID 9915024 DOI: 10.1016/S0264-410X(98)00283-7 |
0.574 |
|
| 1999 |
Vellinga A, Van Damme P, Bruckers L, Weyler JJ, Molenberghs G, Meheus A. Modelling long-term persistence of hepatitis B antibodies after vaccination. Journal of Medical Virology. 57: 100-3. PMID 9892391 DOI: 10.1002/(Sici)1096-9071(199902)57:2<100::Aid-Jmv2>3.0.Co;2-M |
0.615 |
|
| 1998 |
Van Herck K, Van Damme P, Thoelen S, Meheus A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results Vaccine. 16: 1933-1935. PMID 9796046 DOI: 10.1016/S0264-410X(98)00126-1 |
0.8 |
|
| 1998 |
Thoelen S, Van Damme P, Mathei C, Leroux-Roels G, Desombere I, Safary A, Vandepapeliere P, Slaoui M, Meheus A. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system Vaccine. 16: 708-714. PMID 9562690 DOI: 10.1016/S0264-410X(97)00254-5 |
0.573 |
|
| 1998 |
Buma AH, Beutels P, van Damme P, Tormans G, van Doorslaer E, Leentvaar-Kuijpers A. An Economic Evaluation of Hepatitis A Vaccination in Dutch Military Personnel Military Medicine. 163: 564-567. DOI: 10.1093/MILMED/163.8.564 |
0.605 |
|
| 1997 |
Matheï C, Van Damme P, Meheus A. Hepatitis B vaccine administration: Comparison between jet-gun and syringe and needle Vaccine. 15: 402-404. PMID 9141211 DOI: 10.1016/S0264-410X(96)00196-X |
0.546 |
|
| 1997 |
Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national lmmunisation programmes British Medical Journal. 314: 1033-1036. PMID 9112852 DOI: 10.1136/bmj.314.7086.1033 |
0.59 |
|
| 1996 |
Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children Journal of Infectious Diseases. 174. PMID 8896542 DOI: 10.1093/INFDIS/174.SUPPLEMENT_3.S335 |
0.432 |
|
| 1995 |
Van Doorslaer E, Tormans G, Van Damme P. Cost-effectiveness analysis of vaccination against hepatitis A in travellers. Journal of Medical Virology. 44: 463-9. PMID 7897383 DOI: 10.1002/JMV.1890440429 |
0.521 |
|
| 1995 |
Van Damme P, Tormans G, Beutels P, Van Doorslaer E. Hepatitis B prevention in Europe: a preliminary economic evaluation Vaccine. 13. PMID 7571833 DOI: 10.1016/0264-410X(95)80053-G |
0.442 |
|
| 1994 |
Van Damme P, Thoelen S, Cramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis a vaccine: Reactogenicity, immunogenicity, and long-term antibody persistence Journal of Medical Virology. 44: 446-451. PMID 7897379 DOI: 10.1002/jmv.1890440425 |
0.6 |
|
| 1994 |
Van Damme P, Mathei C, Thoelen S, Meheus A, Safary A, Andre FE. Single dose inactivated hepatitis A vaccine: Rationale and clinical assessment of the safety and immunogenicity Journal of Medical Virology. 44: 435-441. PMID 7897376 DOI: 10.1002/jmv.1890440422 |
0.632 |
|
| 1993 |
Van Damme P, Cramm M, Van der Auwera JC, Meheus A. Hepatitis A vaccination for health care workers [18] British Medical Journal. 306: 1615. PMID 8392413 DOI: 10.1136/bmj.306.6892.1615-a |
0.512 |
|
| 1993 |
Tormans G, Van Damme P, Carrin G, Clara R, Eylenbosch W. Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus--the case of Belgium. Social Science & Medicine (1982). 37: 173-81. PMID 8351532 DOI: 10.1016/0277-9536(93)90453-B |
0.43 |
|
| 1993 |
Tormans G, Van Damme P, Van Doorslaer E. Cost-effectiveness analysis of hepatitis A prevention in travellers. Vaccine. S88-92. PMID 1335668 DOI: 10.1016/0264-410X(92)90554-W |
0.532 |
|
| 1992 |
Van Damme P, Cramm M, Safary A, Vandepapelière P, Meheus A. Heat stability of a recombinant DNA hepatitis B vaccine Vaccine. 10: 366-367. PMID 1534639 DOI: 10.1016/0264-410X(92)90064-Q |
0.591 |
|
| 1990 |
Van Damme P, Vranckx R, Meheus A. Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down's syndrome Vaccine. 8. PMID 2139285 DOI: 10.1016/0264-410X(90)90236-F |
0.56 |
|
| 1989 |
Van Damme P, Vranckx R, Safary A, André FE, Meheus A. Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients. The American Journal of Medicine. 87: 26S-29S. PMID 2528294 DOI: 10.1016/0002-9343(89)90527-5 |
0.428 |
|
| Show low-probability matches. |